159989-64-7 | Nelfinavir

Packsize	Purity	Availability	Price	Discounted Price
2mg	98%	in stock	$68.00	$48.00

Description

• Catalog Number: AA82170
• Chemical Name: Nelfinavir
• CAS Number: 159989-64-7
• Molecular Formula: C32H45N3O4S
• Molecular Weight: 567.7824
• MDL Number: MFCD01938163
• SMILES: O[C@@H]([C@@H](NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
• NSC Number: 747167

Computed Properties

• Complexity: 830
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 5
• Heavy Atom Count: 40
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 10
• XLogP3: 5.7

Literature

• The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.

  Arthritis & rheumatology (Hoboken, N.J.) 20180101

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations.

  Antimicrobial agents and chemotherapy 20131101

• Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance.

  Chemistry & biology 20130919

• Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.

  Blood 20130227

• In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.

  The Journal of antimicrobial chemotherapy 20130101

• Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors.

  Cancer letters 20121201

• Relation between flexibility and positively selected HIV-1 protease mutants against inhibitors.

  Proteins 20121201

• Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.

  The Pediatric infectious disease journal 20121101

• Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir.

  Journal of the National Cancer Institute 20121017

• Inhibin beta E is upregulated by drug-induced endoplasmic reticulum stress as a transcriptional target gene of ATF4.

  Toxicology and applied pharmacology 20121015

• The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.

  Journal of leukocyte biology 20121001

• Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.

  Drug metabolism and disposition: the biological fate of chemicals 20120801

• The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.

  Haematologica 20120701

• Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.

  Antimicrobial agents and chemotherapy 20120701

• Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.

  The FEBS journal 20120701

• Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells.

  Cell death & disease 20120701

• Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.

  The New England journal of medicine 20120621

• Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.

  Journal of medicinal chemistry 20120614

• The effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal model.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20120601

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells.

  Journal of chemotherapy (Florence, Italy) 20120601

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20120501

• Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.

  Biopharmaceutics & drug disposition 20120501

• Alternaria fungus induces the production of GM-CSF, interleukin-6 and interleukin-8 and calcium signaling in human airway epithelium through protease-activated receptor 2.

  International archives of allergy and immunology 20120501

• Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.

  Bioorganic & medicinal chemistry letters 20120415

• Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions.

  Pharmaceutical research 20120401

• The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.

  The Journal of antimicrobial chemotherapy 20120401

• Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120401

• A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small cell lung cancer: a report of toxicities and clinical response.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20120401

• HIV exposure through contact with body fluids.

  Prescrire international 20120401

• Matrix metalloproteinase-2 and -9 in glioblastoma: a trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma.

  Archives of medical research 20120401

• Nanotechnology and the treatment of HIV infection.

  Viruses 20120401

• Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20120322

• Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Evaluation of acetylated moth bean starch as a carrier for controlled drug delivery.

  International journal of biological macromolecules 20120301

• Exploring the complexity of the HIV-1 fitness landscape.

  PLoS genetics 20120301

• Transplacental passage of nevirapine, nelfinavir and lopinavir.

  The Netherlands journal of medicine 20120301

• [Comprehensive strategy for retinal neuroprotection. Challenging the clinical application].

  Nippon Ganka Gakkai zasshi 20120301

• Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.

  International journal of epidemiology 20120201

• Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.

  Journal of medical virology 20120201

• The effect of β-carotene supplementation on the pharmacokinetics of nelfinavir and its active metabolite M8 in HIV-1-infected patients.

  Molecules (Basel, Switzerland) 20120112

• Antiretroviral prophylaxis and the risk of cleft lip and palate: preliminary signal detection in the food and drug administration's adverse events reporting system database.

  The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 20120101

• Interaction of calf thymus DNA with the antiviral drug Lamivudine.

  DNA and cell biology 20120101

• Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

  The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.

  Journal of neurochemistry 20120101

• Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

  PloS one 20120101

• Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system.

  Retrovirology 20120101

• Intraepithelial γδ T cells remain increased in the duodenum of AIDS patients despite antiretroviral treatment.

  PloS one 20120101

• Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.

  Frontiers in pharmacology 20120101

• Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments.

  AIDS research and therapy 20120101

• Safety and pharmacokinetics of nelfinavir during the second and third trimesters of pregnancy and postpartum.

  HIV clinical trials 20120101

• Progressive activation of CD127+132- recent thymic emigrants into terminally differentiated CD127-132+ T-cells in HIV-1 infection.

  PloS one 20120101

• Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.

  BMC clinical pharmacology 20120101

• Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.

  AIDS research and therapy 20120101

• Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.

  PloS one 20120101

• Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.

  Substance abuse treatment, prevention, and policy 20120101

• Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.

  Scientific reports 20120101

• Computable features required to evaluate the efficacy of drugs and a universal algorithm to find optimally effective drug in a drug complex.

  PloS one 20120101

• Determinants of Adherence to Antiretroviral Therapy among HIV-Infected Patients in Africa.

  AIDS research and treatment 20120101

• Associations between HIV and human pathways revealed by protein-protein interactions and correlated gene expression profiles.

  PloS one 20120101

• Therapeutic potential of HIV protease-activable CASP3.

  Scientific reports 20120101

• Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India.

  AIDS research and treatment 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.

  PloS one 20120101

• Treatment of Kaposi sarcoma-associated herpesvirus-associated cancers.

  Frontiers in microbiology 20120101

• Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz.

  Infectious diseases in obstetrics and gynecology 20120101

• Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment.

  Clinical & developmental immunology 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.

  AIDS research and treatment 20120101

• Trends in Decline of Antiretroviral Resistance among ARV-Experienced Patients in the HIV Outpatient Study: 1999-2008.

  AIDS research and treatment 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India.

  ISRN pediatrics 20120101

• Maternal CD4+ cell count decline after interruption of antiretroviral prophylaxis for the prevention of mother-to-child transmission of HIV.

  PloS one 20120101

• T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384.

  PloS one 20120101

• Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.

  The Southeast Asian journal of tropical medicine and public health 20120101

• Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs.

  Alcoholism, clinical and experimental research 20111201

• Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.

  Journal of acquired immune deficiency syndromes (1999) 20111201

• Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20111201

• Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.

  The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20111201

• Qualitative prediction of blood-brain barrier permeability on a large and refined dataset.

  Journal of computer-aided molecular design 20111201

• Protease inhibitor-associated QT interval prolongation.

  The Annals of pharmacotherapy 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• Diagnosis & treatment of tuberculosis in HIV co-infected patients.

  The Indian journal of medical research 20111201

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.

  Cancer chemotherapy and pharmacology 20111101

• Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.

  Journal of acquired immune deficiency syndromes (1999) 20111101

• Prediction of drug-resistance in HIV-1 subtype C based on protease sequences from ART naive and first-line treatment failures in North India using genotypic and docking analysis.

  Antiviral research 20111101

• In vitro activity of antiretroviral drugs against Plasmodium falciparum.

  Antimicrobial agents and chemotherapy 20111101

• Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular and miscellaneous anti-infective agents.

  Clinical pharmacokinetics 20111101

• Elucidating the energetics of entropically driven protein-ligand association: calculations of absolute binding free energy and entropy.

  The journal of physical chemistry. B 20111020

• Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20111001

• Nelfinavir induces radiation sensitization in pituitary adenoma cells.

  Cancer biology & therapy 20111001

• The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.

  PLoS pathogens 20111001

• Structural features determining the intestinal epithelial permeability and efflux of novel HIV-1 protease inhibitors.

  Journal of pharmaceutical sciences 20110901

• Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.

  The Pediatric infectious disease journal 20110901

• Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.

  Current cancer drug targets 20110901

• Targeting the off-targets: a computational bioinformatics approach to understanding the polypharmacology of nelfinavir.

  Expert review of clinical pharmacology 20110901

• Modulation of CCAAT/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).

  The Journal of biological chemistry 20110819

• HIV-protease inhibitors block the replication of both vesicular stomatitis and influenza viruses at an early post-entry replication step.

  Virology 20110815

• Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.

  British journal of cancer 20110809

• Genetic diversity of HIV type 1 in Montenegro.

  AIDS research and human retroviruses 20110801

• Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment.

  Current opinion in infectious diseases 20110801

• The progress made in determining the Mycobacterium tuberculosis structural proteome.

  Proteomics 20110801

• Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa.

  Journal of health, population, and nutrition 20110801

• Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.

  Bioorganic & medicinal chemistry 20110701

• LC, LC-MS/TOF and MS(n) studies for the identification and characterization of degradation products of nelfinavir mesylate.

  Journal of pharmaceutical and biomedical analysis 20110601

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.

  Drug metabolism and disposition: the biological fate of chemicals 20110601

• Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution.

  AAPS PharmSciTech 20110601

• Predicting binding to p-glycoprotein by flexible receptor docking.

  PLoS computational biology 20110601

• Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.

  European journal of clinical pharmacology 20110501

• HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• Human immunodeficiency virus therapeutics and pharmacogenomics.

  Indian journal of human genetics 20110501

• [Effects of daily administration of a stavudine/nelfinavir association on the fetuses and placentas of female albino rats].

  Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 20110501

• Proper laboratory notebook practices: protecting your intellectual property.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401

• Within-host co-evolution of Gag P453L and protease D30N/N88D demonstrates virological advantage in a highly protease inhibitor-exposed HIV-1 case.

  Antiviral research 20110401

• Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials.

  Clinical pharmacokinetics 20110401

• Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20110401

• The International Interlaboratory Quality Control Program for Measurement of Antiretroviral Drugs in Plasma: a global proficiency testing program.

  Therapeutic drug monitoring 20110401

• Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.

  PLoS computational biology 20110401

• Clinical applications of drug desensitization in the Asia-Pacific region.

  Asia Pacific allergy 20110401

• Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy.

  Rare tumors 20110330

• A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation.

  Journal of pharmaceutical and biomedical analysis 20110325

• Maximum likelihood estimation of long-term HIV dynamic models and antiviral response.

  Biometrics 20110301

• Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.

  Drug metabolism and disposition: the biological fate of chemicals 20110301

• HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

  Current HIV/AIDS reports 20110301

• Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.

  Pharmacotherapy 20110301

• Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding--the Kisumu Breastfeeding Study, Kenya: a clinical trial.

  PLoS medicine 20110301

• HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis.

  PLoS medicine 20110301

• The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors.

  Memorias do Instituto Oswaldo Cruz 20110301

• Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

  Drug metabolism and disposition: the biological fate of chemicals 20110201

• Glyceroneogenesis is inhibited through HIV protease inhibitor-induced inflammation in human subcutaneous but not visceral adipose tissue.

  Journal of lipid research 20110201

• Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.

  Therapeutic drug monitoring 20110201

• Radiosensitivity of human papillomavirus-related tumors: in regard to Gupta et al. (Int J Radiat Oncol Biol Phys 2009;74:928-933).

  International journal of radiation oncology, biology, physics 20110201

• Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.

  Journal of acquired immune deficiency syndromes (1999) 20110201

• Episomal viral cDNAs identify a reservoir that fuels viral rebound after treatment interruption and that contributes to treatment failure.

  PLoS pathogens 20110201

• From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients.

  Journal of clinical medicine research 20110201

• Determination of the antiretroviral drug nevirapine in diluted alkaline electrolyte by adsorptive stripping voltammetry at the mercury film electrode.

  Combinatorial chemistry & high throughput screening 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• A comparison of the MOS-HIV and SF-12v2 for measuring health-related quality of life of men and women living with HIV/AIDS.

  AIDS research and therapy 20110101

• Human immunodeficiency virus type 2 in two Saudi families.

  Annals of Saudi medicine 20110101

• Analysis of nelfinavir-induced endoplasmic reticulum stress.

  Methods in enzymology 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

  PloS one 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• Acute toxicity of second generation HIV protease-inhibitors in combination with radiotherapy: a retrospective case series.

  Radiation oncology (London, England) 20110101

• High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.

  Journal of the International AIDS Society 20110101

• Machine learning on normalized protein sequences.

  BMC research notes 20110101

• Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.

  European journal of medical research 20110101

• Activation of latent HIV using drug-loaded nanoparticles.

  PloS one 20110101

• Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.

  European journal of medical research 20110101

• Tinea incognito Caused by Microsporum gypseum in a Patient with Advanced HIV Infection: A Case Report.

  Case reports in dermatology 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.

  Breast cancer : basic and clinical research 20110101

• HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy.

  PloS one 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• Safety and tolerability of antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20110101

• Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.

  PloS one 20110101

• HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

  The open medicinal chemistry journal 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

  PloS one 20110101

• Tolvaptan, hyponatremia, and heart failure.

  International journal of nephrology and renovascular disease 20110101

• Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load.

  PloS one 20110101

• 12-month mortality and loss-to-program in antiretroviral-treated children: The IeDEA pediatric West African Database to evaluate AIDS (pWADA), 2000-2008.

  BMC public health 20110101

• Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients.

  European journal of medical research 20110101

• Non-cirrhotic portal hypertension in human immunodeficiency virus-infected patients: a new challenge in antiretroviral therapy era.

  The open AIDS journal 20110101

• Does HAART efficacy translate to effectiveness? Evidence for a trial effect.

  PloS one 20110101

• Clinical therapeutics in pregnancy.

  Journal of biomedicine & biotechnology 20110101

• Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

  BMC pediatrics 20110101

• HIV-1 mutational pathways under multidrug therapy.

  AIDS research and therapy 20110101

• Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

  PloS one 20110101

• Induction maintenance concept for HAART as initial treatment in HIV infected infants.

  European journal of medical research 20110101

• Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis.

  PloS one 20110101

• Prevention of perinatal HIV transmission: the Perinatal HIV Hotline perspective.

  Topics in antiviral medicine 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Recent developments of peptidomimetic HIV-1 protease inhibitors.

  Current medicinal chemistry 20110101

• HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.

  Retrovirology 20110101

• HIV-Associated Venous Thromboembolism.

  Mediterranean journal of hematology and infectious diseases 20110101

• Choosing the right cell line for breast cancer research.

  Breast cancer research : BCR 20110101

• HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.

  PloS one 20110101

• Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.

  PloS one 20110101

• X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI.

  PloS one 20110101

• Identification of novel functional inhibitors of acid sphingomyelinase.

  PloS one 20110101

• Kinetics of the viral cycle influence pharmacodynamics of antiretroviral therapy.

  Biology direct 20110101

• Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.

  BMC public health 20110101

• Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review.

  Journal of medical case reports 20110101

• Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

  PloS one 20110101

• Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.

  Journal of thyroid research 20110101

• Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy.

  Indian journal of sexually transmitted diseases and AIDS 20110101

• Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature.

  Indian journal of urology : IJU : journal of the Urological Society of India 20110101

• Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus.

  Journal of pharmacology & pharmacotherapeutics 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Human immunodeficiency virus endocrinopathy.

  Indian journal of endocrinology and metabolism 20110101

• Choosing a gliptin.

  Indian journal of endocrinology and metabolism 20110101

• Restricted Kaposi's sarcoma (KS) herpesvirus transcription in KS lesions from patients on successful antiretroviral therapy.

  mBio 20110101

• Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

  PloS one 20110101

• Complete Healing of a Giant Wart in a Severely Immune-Compromised Patient with HIV Infection Treated with Acupuncture.

  Case reports in dermatology 20110101

• Optimal antiviral switching to minimize resistance risk in HIV therapy.

  PloS one 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• Identification and characterization of genes involved in leishmania pathogenesis: the potential for drug target selection.

  Molecular biology international 20110101

• Low intracellular ATP levels exacerbate carcinogen-induced inflammatory stress response and inhibit in vitro tubulogenesis in human brain endothelial cells.

  Journal of inflammation research 20110101

• Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.

  HIV/AIDS (Auckland, N.Z.) 20110101

• TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes.

  PloS one 20110101

• National prevalence and trends of HIV transmitted drug resistance in Mexico.

  PloS one 20110101

• AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

  BMC research notes 20110101

• Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

  Retrovirology 20110101

• Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.

  PloS one 20110101

• Cost-effectiveness analysis of initial HIV treatment under Italian guidelines.

  ClinicoEconomics and outcomes research : CEOR 20110101

• Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.

  BMC infectious diseases 20110101

• A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes.

  BMC bioinformatics 20110101

• Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study.

  BMC pulmonary medicine 20110101

• Critical appraisal of ticagrelor in the management of acute coronary syndrome.

  Therapeutics and clinical risk management 20110101

• Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.

  International journal of nanomedicine 20110101

• Acute HIV Infection in Pregnancy: The Case for Third Trimester Rescreening.

  Case reports in infectious diseases 20110101

• Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma.

  Indian journal of pharmaceutical sciences 20110101

• Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Effects of HIV aspartyl-proteinase inhibitors on Leishmania sp.

  Experimental parasitology 20101201

• Estimating causal effects using prior information on nontrial treatments.

  Clinical trials (London, England) 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy.

  Cancer science 20101201

• HIV capsid is a tractable target for small molecule therapeutic intervention.

  PLoS pathogens 20101201

• Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai.

  The Indian journal of medical research 20101201

• Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir.

  Biochemical and biophysical research communications 20101105

• Stress degradation studies of nelfinavir mesylate by Fourier transform infrared spectroscopy.

  Journal of pharmaceutical and biomedical analysis 20101102

• Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.

  Sexually transmitted diseases 20101101

• HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.

  Journal of molecular and cellular cardiology 20101101

• Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.

  The Journal of antimicrobial chemotherapy 20101101

• Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.

  Cancer chemotherapy and pharmacology 20101101

• Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats.

  Circulation 20101101

• Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

  Viruses 20101101

• Molecular Basis for Drug Resistance in HIV-1 Protease.

  Viruses 20101101

• Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.

  Investigational new drugs 20101001

• ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.

  International journal of colorectal disease 20101001

• Synergistic antiviral effect of Galanthus nivalis agglutinin and nelfinavir against feline coronavirus.

  Antiviral research 20101001

• Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.

  Journal of veterinary pharmacology and therapeutics 20101001

• Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.

  Journal of Korean medical science 20101001

• pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions.

  The Journal of pharmacology and experimental therapeutics 20100901

• Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.

  Journal of molecular graphics & modelling 20100901

• Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir.

  European journal of obstetrics, gynecology, and reproductive biology 20100901

• Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots.

  Analytical and bioanalytical chemistry 20100901

• Ultraviolet photodissociation of protonated pharmaceuticals in a pressurized linear quadrupole ion trap.

  Rapid communications in mass spectrometry : RCM 20100815

• Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.

  Antimicrobial agents and chemotherapy 20100801

• A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.

  Clinical chemistry and laboratory medicine 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Discovery of orally available spirodiketopiperazine-based CCR5 antagonists.

  Bioorganic & medicinal chemistry 20100715

• CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20100701

• New prospects for nelfinavir in non-HIV-related diseases.

  Current molecular pharmacology 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Mass spectrometry and renal calculi.

  Journal of medicine and life 20100515

• Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme.

  HIV medicine 20100501

• Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance.

  Journal of virology 20100501

• Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.

  Drug safety 20100401

• Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes.

  Biopharmaceutics & drug disposition 20100301

• Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

  PLoS neglected tropical diseases 20100301

• Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.

  Journal of medicinal chemistry 20100225

• HIV protease inhibitors block oral epithelial cell DNA synthesis.

  Archives of oral biology 20100201

• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  The Journal of infectious diseases 20100201

• Radiosensitization of epidermal growth factor receptor/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20100201

• HIV Genetic Diversity and Drug Resistance.

  Viruses 20100201

• Asymmetric synthesis of the potent HIV-protease inhibitor, nelfinavir.

  The Journal of organic chemistry 20100115

• Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.

  AIDS (London, England) 20100102

• Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS.

  Journal of molecular graphics & modelling 20100101

• HIV protease inhibitors, indinavir or nelfinavir, augment antimalarial action of artemisinin in vitro.

  The American journal of tropical medicine and hygiene 20100101

• Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia.

  Annals of Saudi medicine 20100101

• The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.

  Molecular cancer 20100101

• Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy.

  International journal of cell biology 20100101

• Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

  Journal of the International AIDS Society 20100101

• Abacavir/lamivudine combination in the treatment of HIV: a review.

  Therapeutics and clinical risk management 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• Increasing rates of obesity among HIV-infected persons during the HIV epidemic.

  PloS one 20100101

• Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

  Molecular cancer 20100101

• Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients.

  Patient preference and adherence 20100101

• Dynamics of lamin-A processing following precursor accumulation.

  PloS one 20100101

• An assay to monitor HIV-1 protease activity for the identification of novel inhibitors in T-cells.

  PloS one 20100101

• Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors.

  PloS one 20100101

• Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.

  Breast cancer research : BCR 20100101

• Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry.

  PloS one 20100101

• Identifying individuals with virologic failure after initiating effective antiretroviral therapy: The surprising value of mean corpuscular hemoglobin in a cross-sectional study.

  AIDS research and therapy 20100101

• Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.

  BMC bioinformatics 20100101

• Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

  BMC gastroenterology 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.

  PloS one 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Aging, human immunodeficiency virus, and bone health.

  Clinical interventions in aging 20100101

• Human immunodeficiency virus and leishmaniasis.

  Journal of global infectious diseases 20100101

• Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C.

  Retrovirology 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.

  Core evidence 20100101

• Treatment and disease progression in a birth cohort of vertically HIV-1 infected children in Ukraine.

  BMC pediatrics 20100101

• Quantitative analysis of tumor vascular structure after drug treatment.

  Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference 20100101

• In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.

  Antiviral therapy 20100101

• Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database.

  BMC infectious diseases 20100101

• Saxagliptin for type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients.

  AIDS research and treatment 20100101

• In Vivo validation of a bioinformatics based tool to identify reduced replication capacity in HIV-1.

  The open medical informatics journal 20100101

• Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.

  HIV/AIDS (Auckland, N.Z.) 20100101

• HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• New and emerging agents in the management of lipodystrophy in HIV-infected patients.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor.

  Journal of blood medicine 20100101

• Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir.

  European journal of obstetrics, gynecology, and reproductive biology 20091201

• Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20091201

• New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation.

  Antimicrobial agents and chemotherapy 20091201

• Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats.

  Biopharmaceutics & drug disposition 20091201

• Mitochondrial T9098C sequence change in the MTATP6 gene and development of severe mitochondrial disease after in utero antiretroviral prophylaxis.

  Pharmacotherapy 20091201

• Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.

  Journal of Korean medical science 20091201

• Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir.

  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20091201

• HIV-1 Protease: Structural Perspectives on Drug Resistance.

  Viruses 20091201

• Current and Novel Inhibitors of HIV Protease.

  Viruses 20091201

• Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.

  Biochemical and biophysical research communications 20091113

• EMS in Viracept--initial ('traditional') assessment of risk to patients based on linear dose response relations.

  Toxicology letters 20091112

• General 4-week toxicity study with EMS in the rat.

  Toxicology letters 20091112

• Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.

  Toxicology letters 20091112

• In vivo and in vitro characterization of ethyl methanesulfonate pharmacokinetics in animals and in human.

  Toxicology letters 20091112

• Modelling of patient EMS exposure: translating pharmacokinetics of EMS in vitro and in animals into patients.

  Toxicology letters 20091112

• The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?

  Toxicology letters 20091112

• EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.

  Toxicology letters 20091112

• What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.

  Toxicology letters 20091112

• Literature review on the genotoxicity, reproductive toxicity, and carcinogenicity of ethyl methanesulfonate.

  Toxicology letters 20091112

• In vivo genotoxicity of EMS: statistical assessment of the dose response curves.

  Toxicology letters 20091112

• The Viracept-EMS case: impact and outlook.

  Toxicology letters 20091112

• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  Journal of pharmaceutical sciences 20091101

• Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus study.

  Journal of acquired immune deficiency syndromes (1999) 20091101

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite.

  British journal of clinical pharmacology 20091101

• Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.

  Current HIV research 20091101

• Antiretroviral compounds and cholesterol efflux from macrophages.

  Atherosclerosis 20091001

• Prolonged chronic phase of greater than 10 years of chronic myelogenous leukemia in a patient with congenital human immunodefeciency virus infection.

  Pediatric blood & cancer 20091001

• Antiretroviral protease inhibitors potentiate chloroquine antimalarial activity in malaria parasites by regulating intracellular glutathione metabolism.

  Experimental parasitology 20091001

• A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.

  Journal of medical virology 20091001

• Signaling pathways in adenoid cystic cancers: implications for treatment.

  Cancer biology & therapy 20091001

• Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

  PLoS computational biology 20091001

• The key role of genomics in modern vaccine and drug design for emerging infectious diseases.

  PLoS genetics 20091001

• Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress.

  Cancer letters 20090908

• Fulminant hepatic failure associated with antiretroviral therapy in a pregnant woman.

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20090901

• Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.

  Current clinical pharmacology 20090901

• The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.

  Basic & clinical pharmacology & toxicology 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• Effects of antiretroviral drug recall on perception of therapy benefits and on adherence to antiretroviral treatment in HIV-infected children.

  Current HIV research 20090901

• Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090815

• Pregnancy does not increase CYP3A or P-glycoprotein activity in the non-human primate, Macaca nemestrina.

  The Journal of pharmacology and experimental therapeutics 20090801

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.

  The Cochrane database of systematic reviews 20090708

• Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.

  Journal of viral hepatitis 20090701

• Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals.

  Antimicrobial agents and chemotherapy 20090701

• The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT.

  International journal of radiation oncology, biology, physics 20090701

• Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes.

  AIDS patient care and STDs 20090701

• CD4 responses in the setting or suboptimal virological responses to antiretroviral therapy: features, outcomes, and associated factors.

  AIDS research and human retroviruses 20090701

• Pharmacokinetic study and comparative bioavailability of two nelfinavir tablet formulations in Iranian healthy volunteers after a low-dose administration.

  International journal of clinical pharmacology and therapeutics 20090701

• Effectiveness of commercial inhibitors against subtype F HIV-1 protease.

  Journal of enzyme inhibition and medicinal chemistry 20090601

• Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.

  Endocrinology 20090601

• As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrina.

  The Journal of pharmacology and experimental therapeutics 20090601

• Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.

  The Journal of antimicrobial chemotherapy 20090601

• Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.

  Proteins 20090515

• The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

  Antiviral research 20090501

• Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

  Journal of computer-aided molecular design 20090501

• Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

  Drug and alcohol dependence 20090501

• Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis.

  American journal of physiology. Gastrointestinal and liver physiology 20090501

• Nelfinavir+M8 plasma levels determined with an ELISA test in HIV infected patients with or without HCV and/or HBV coinfection: the VIRAKINETICS II study.

  Current HIV research 20090501

• Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer.

  Current oncology (Toronto, Ont.) 20090501

• Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

  Lancet (London, England) 20090418

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone.

  Experimental biology and medicine (Maywood, N.J.) 20090401

• The influence of the patients' educational levels on socioeconomic, clinical, immunological and virological endpoints.

  AIDS care 20090401

• A mass spectrometry based imaging method developed for the intracellular detection of HIV protease inhibitors.

  Rapid communications in mass spectrometry : RCM 20090401

• Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats.

  Canadian journal of physiology and pharmacology 20090401

• GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

  Antimicrobial agents and chemotherapy 20090301

• Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

  Drug metabolism and disposition: the biological fate of chemicals 20090301

• Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.

  The Journal of antimicrobial chemotherapy 20090301

• Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study.

  Journal of clinical pharmacology 20090301

• Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.

  PLoS pathogens 20090301

• Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090215

• Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes--relevance for partial lipodystrophy.

  American journal of physiology. Endocrinology and metabolism 20090201

• Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis.

  Cancer biology & therapy 20090201

• Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.

  Biological & pharmaceutical bulletin 20090201

• Warfarin-antiretroviral interactions.

  The Annals of pharmacotherapy 20090201

• Nelfinavir: a magic bullet to annihilate cancer cells?

  Cancer biology & therapy 20090201

• Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors.

  Transfusion 20090101

• Contraception and HIV infection in women.

  Human reproduction update 20090101

• Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection.

  Clinical chemistry 20090101

• WNT/beta-catenin signaling is involved in regulation of osteoclast differentiation by human immunodeficiency virus protease inhibitor ritonavir: relationship to human immunodeficiency virus-linked bone mineral loss.

  The American journal of pathology 20090101

• The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

  PPAR research 20090101

• Anti-HIV drugs for cancer therapeutics: back to the future?

  The Lancet. Oncology 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• Universal access: the benefits and challenges in bringing integrated HIV care to isolated and conflict affected populations in the Republic of Congo.

  Conflict and health 20090101

• Long-term evaluation of glucose homeostasis in a cohort of HAART-treated HIV-infected children: a longitudinal, observational cohort study.

  Clinical drug investigation 20090101

• Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

  AIDS research and therapy 20090101

• Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART).

  European journal of medical research 20090101

• Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.

  Retrovirology 20090101

• Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.

  PloS one 20090101

• Darunavir: a review of its use in the management of HIV infection in adults.

  Drugs 20090101

• HIV aspartyl peptidase inhibitors interfere with cellular proliferation, ultrastructure and macrophage infection of Leishmania amazonensis.

  PloS one 20090101

• Is PPARγ a prospective player in HIV-1-associated bone disease?

  PPAR research 20090101

• Zidovudine, lamivudine, and nelfinavir concentrations in amniotic fluid and maternal serum.

  HIV clinical trials 20090101

• Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

  European journal of medical research 20090101

• Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells.

  Molecular cancer 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

  PloS one 20090101

• Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

  BMC infectious diseases 20090101

• Clinicians' knowledge of 2007 Food and Drug Administration recommendation to discontinue nelfinavir use during pregnancy.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study.

  AIDS research and therapy 20090101

• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

  PloS one 20090101

• Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008).

  Journal of the International AIDS Society 20090101

• Development of a nursing intervention to facilitate optimal antiretroviral-treatment taking among people living with HIV.

  BMC health services research 20090101

• Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV.

  Journal of the International AIDS Society 20090101

• Host sequence motifs shared by HIV predict response to antiretroviral therapy.

  BMC medical genomics 20090101

• New options in the treatment of lipid disorders in HIV-infected patients.

  The open AIDS journal 20090101

• Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.

  AIDS research and therapy 20090101

• The Impact of HIV and Malaria Coinfection: What Is Known and Suggested Venues for Further Study.

  Interdisciplinary perspectives on infectious diseases 20090101

• Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model.

  AIDS research and therapy 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy.

  BMC infectious diseases 20090101

• Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response.

  PloS one 20090101

• Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.

  BMC bioinformatics 20090101

• Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

  Retrovirology 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Pulmonary nocardiosis in the acquired immunodeficiency syndrome, computed tomographic findings: a case report.

  Cases journal 20090101

• Vertebral compression fractures in an HIV-positive patient with steroid-induced Cushing syndrome: a case report.

  Cases journal 20090101

• High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia in HIV-infected Japanese individuals based on in vivo and in vitro analyses.

  Internal medicine (Tokyo, Japan) 20090101

• Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy.

  BMC infectious diseases 20090101

• Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.

  Journal of the International AIDS Society 20090101

• Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.

  BMC bioinformatics 20090101

• Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

  Journal of biomedicine & biotechnology 20090101

• The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia.

  The open virology journal 20090101

• HIV associated thrombocytopenia, misdiagnosed as thrombotic thrombocytopenic purpura: a case report.

  Cases journal 20090101

• German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

  European journal of medical research 20090101

• Hepatic profile analyses of tipranavir in Phase II and III clinical trials.

  BMC infectious diseases 20090101

• Formulation preference, tolerability and quality of life assessment following a switch from lopinavir/ritonavir soft gel capsule to tablet in human immunodeficiency virus-infected patients.

  AIDS research and therapy 20090101

• Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.

  AIDS research and therapy 20090101

• Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

  PloS one 20090101

• A comprehensive review of immunosuppression used for liver transplantation.

  Journal of transplantation 20090101

• Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20090101

• Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.

  HIV clinical trials 20090101

• Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal.

  The open AIDS journal 20090101

• Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma.

  Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20090101

• Role of darunavir in the management of HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Limited-sampling strategies for anti-infective agents: systematic review.

  The Canadian journal of hospital pharmacy 20090101

• Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.

  Biochemical and biophysical research communications 20081226

• Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.

  Journal of pharmaceutical sciences 20081201

• A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.

  Drug metabolism and disposition: the biological fate of chemicals 20081201

• An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.

  Therapeutic drug monitoring 20081201

• PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.

  Journal of medical virology 20081201

• Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients.

  Therapeutics and clinical risk management 20081201

• Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome.

  Biologics : targets & therapy 20081201

• Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum.

  HIV medicine 20081101

• Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.

  International journal of clinical practice 20081101

• Intracellular survival of Leishmania species that cause visceral leishmaniasis is significantly reduced by HIV-1 protease inhibitors.

  The Journal of infectious diseases 20081101

• Evolutionary modeling of rate shifts reveals specificity determinants in HIV-1 subtypes.

  PLoS computational biology 20081101

• Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

  AIDS (London, England) 20081101

• Effect of streptozotocin-induced diabetes mellitus on the pharmacokinetics of nelfinavir in rats.

  Biopharmaceutics & drug disposition 20081101

• Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission.

  AIDS research and human retroviruses 20081101

• Repositioning HIV protease inhibitors as cancer therapeutics.

  Current opinion in HIV and AIDS 20081101

• Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.

  The Journal of antimicrobial chemotherapy 20081001

• Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

  Therapeutic drug monitoring 20081001

• Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications.

  Therapeutic drug monitoring 20081001

• Bullous skin eruption in an HIV patient during antiretroviral drugs therapy.

  Dermatologic therapy 20081001

• Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

  Therapeutics and clinical risk management 20081001

• Speeding up the evaluation of new agents in cancer.

  Journal of the National Cancer Institute 20080903

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

  Journal of medicinal chemistry 20080814

• Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.

  Drug metabolism and disposition: the biological fate of chemicals 20080801

• Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

  British journal of clinical pharmacology 20080801

• Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors.

  Antimicrobial agents and chemotherapy 20080801

• Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction.

  Therapeutic drug monitoring 20080801

• Synthesis and biological evaluation of novel isopropanolamine derivatives as non-peptide human immunodeficiency virus protease inhibitors.

  Chemical & pharmaceutical bulletin 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Combating HIV resistance - focus on darunavir.

  Therapeutics and clinical risk management 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.

  European journal of medicinal chemistry 20080701

• Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir.

  Drug metabolism and disposition: the biological fate of chemicals 20080701

• Possible antiretroviral therapy-warfarin drug interaction.

  Pharmacotherapy 20080701

• Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared.

  PLoS medicine 20080701

• (S)-1,5-Dibenzyl-3-tert-butyl-imidazol-idin-4-one.

  Acta crystallographica. Section E, Structure reports online 20080701

• Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus.

  British journal of cancer 20080603

• HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

  The Journal of clinical investigation 20080602

• Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.

  European journal of pediatrics 20080601

• Quality control of protease inhibitors.

  Journal of pharmaceutical sciences 20080601

• BCRP/ABCG2 in the placenta: expression, function and regulation.

  Pharmaceutical research 20080601

• Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.

  The Journal of antimicrobial chemotherapy 20080601

• Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives.

  The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20080601

• Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080601

• Screening and Management of HIV-2-Infected Individuals in Northern Italy.

  AIDS patient care and STDs 20080601

• Atriplatrade mark - HIV therapy in one pill.

  Therapeutics and clinical risk management 20080601

• Paediatric and perinatal HIV/AIDS in Jamaica an international leadership initiative, 2002-2007.

  The West Indian medical journal 20080601

• Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.

  Journal of medicinal chemistry 20080522

• Analysis of correlated mutations in HIV-1 protease using spectral clustering.

  Bioinformatics (Oxford, England) 20080515

• Quantitative analysis of HIV-1 protease inhibitors in cell lysates using MALDI-FTICR mass spectrometry.

  Analytical chemistry 20080515

• Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.

  Cancer biology & therapy 20080501

• Drug-specific effect of nelfinavir and stavudine on primary culture of human preadipocytes.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.

  The Pediatric infectious disease journal 20080501

• Progress towards the use of HIV protease inhibitors in cancer therapy.

  Cancer biology & therapy 20080501

• Implications of gender and pregnancy for antiretroviral drug dosing.

  Current opinion in HIV and AIDS 20080501

• Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.

  Journal of computational chemistry 20080415

• Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

  British journal of clinical pharmacology 20080401

• Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.

  Antimicrobial agents and chemotherapy 20080401

• Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

  Chemical biology & drug design 20080401

• 'One pill, once daily': what clinicians need to know about Atriplatrade mark.

  Therapeutics and clinical risk management 20080401

• Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.

  The Journal of infectious diseases 20080315

• Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.

  Biopharmaceutics & drug disposition 20080301

• Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

  HIV medicine 20080301

• Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.

  Clinical pharmacology and therapeutics 20080201

• Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20080201

• Normal human primary CD4+ T lymphocytes synthesize and release functional osteoprotegerin in vitro.

  Laboratory investigation; a journal of technical methods and pathology 20080201

• Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.

  Contraception 20080201

• Trace determination of ethyl methanesulfonate in Viracept 250 mg tablets by gas chromatography-mass spectrometry.

  Pharmeuropa scientific notes 20080201

• Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

  Therapeutics and clinical risk management 20080201

• The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease.

  Biochemistry 20080115

• Synthesis, anti-HIV and antitubercular activities of nelfinavir diester derivatives.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20080101

• The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane.

  Kidney international 20080101

• Nelfinavir monotherapy increases naïve T-cell numbers in HIV-negative healthy young adults.

  Frontiers in bioscience : a journal and virtual library 20080101

• Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.

  Autophagy 20080101

• Estimation of an in vivo fitness landscape experienced by HIV-1 under drug selective pressure useful for prediction of drug resistance evolution during treatment.

  Bioinformatics (Oxford, England) 20080101

• Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.

  Pharmacotherapy 20080101

• Oral adverse effects due to the use of Nevirapine.

  The journal of contemporary dental practice 20080101

• Drug interactions between HIV protease inhibitors and acid-reducing agents.

  Clinical pharmacokinetics 20080101

• Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.

  Retrovirology 20080101

• Going beyond efficacy: strategies for cancer pain management.

  Current oncology (Toronto, Ont.) 20080101

• Highly active antiretroviral therapy does not affect mitochondrial beta-oxidation of fatty acids: an in vitro study in fibroblasts.

  Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

  Journal of neurovirology 20080101

• Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir.

  BMC neuroscience 20080101

• Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

  BMC infectious diseases 20080101

• Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy.

  Retrovirology 20080101

• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

  AIDS research and therapy 20080101

• Proteochemometric modeling of HIV protease susceptibility.

  BMC bioinformatics 20080101

• [Novel synthesis and spectral characterization of nelfinavir].

  Guang pu xue yu guang pu fen xi = Guang pu 20080101

• Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

  PloS one 20080101

• Infected cell killing by HIV-1 protease promotes NF-kappaB dependent HIV-1 replication.

  PloS one 20080101

• Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.

  HIV clinical trials 20080101

• Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report.

  Retrovirology 20080101

• Pharmacokinetic monitoring of HIV-1 protease inhibitors in the antiretroviral therapy.

  Acta poloniae pharmaceutica 20080101

• Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.

  Antiviral therapy 20080101

• Changes are recommended in use of nelfinavir.

  HIV clinician 20080101

• HIV replication enhances production of free fatty acids, low density lipoproteins and many key proteins involved in lipid metabolism: a proteomics study.

  PloS one 20080101

• Same patient, new stone composition: amprenavir urinary stone.

  Antiviral therapy 20080101

• Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.

  Antiviral therapy 20080101

• Type I interferon-dependent gene MxA in perinatal HIV-infected patients under antiretroviral therapy as marker for therapy failure and blood plasmacytoid dendritic cells depletion.

  Journal of translational medicine 20080101

• Significant improvements in self-reported gastrointestinal tolerability, quality of life, patient satisfaction, and adherence with lopinavir/ritonavir tablet formulation compared with soft gel capsules.

  AIDS research and therapy 20080101

• The levator aponeurosis exposed.

  Ophthalmic plastic and reconstructive surgery 20080101

• A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.

  Radiation oncology (London, England) 20080101

• [Outcome of HIV-infected patients of peritoneal dialysis: experience in a center and literature review].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20080101

• Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy.

  PloS one 20080101

• Beneficial effects of HIV peptidase inhibitors on Fonsecaea pedrosoi: promising compounds to arrest key fungal biological processes and virulence.

  PloS one 20080101

• Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir.

  Pharmacology 20080101

• Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.

  BMC infectious diseases 20080101

• Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy.

  BMC medical research methodology 20080101

• 25 years of HIV-1 research - progress and perspectives.

  BMC medicine 20080101

• Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report.

  Journal of medical case reports 20080101

• Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia.

  BMC pediatrics 20080101

• Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.

  PloS one 20080101

• Comparative studies on inhibitors of HIV protease: a target for drug design.

  In silico biology 20080101

• Prevention and treatment of urinary tract infection with probiotics: Review and research perspective.

  Indian journal of urology : IJU : journal of the Urological Society of India 20080101

• [Dietary recommendations with practical examples of menus for people living with HIV/AIDS in sub-Saharan Africa].

  The Pan African medical journal 20080101

• Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.

  Journal of molecular biology 20071207

• Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.

  The Journal of infectious diseases 20071201

• Human immunodeficiency virus postexposure prophylaxis for occupational exposure in a medical school hospital in Thailand.

  The Journal of hospital infection 20071201

• Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.

  AIDS patient care and STDs 20071201

• Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.

  AIDS research and human retroviruses 20071201

• Characterization of HIV-1 subtypes and viral antiretroviral drug resistance in men who have sex with men in Beijing, China.

  AIDS (London, England) 20071201

• Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.

  AIDS (London, England) 20071130

• HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115

• HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.

  Cancer research 20071115

• Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.

  European journal of clinical pharmacology 20071101

• Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.

  Journal of medical virology 20071101

• Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition.

  Clinical and vaccine immunology : CVI 20071101

• Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.

  British journal of clinical pharmacology 20071101

• Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

  PLoS medicine 20071101

• Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.

  The American journal of the medical sciences 20071101

• An evolutionary-network model reveals stratified interactions in the V3 loop of the HIV-1 envelope.

  PLoS computational biology 20071101

• Promoter polymorphisms and allelic imbalance in ABCB1 expression.

  Pharmacogenetics and genomics 20071101

• Pfizer warns health care professionals of possible carcinogen in Viracept.

  The AIDS reader 20071101

• European license for Viracept re-established by EC.

  AIDS patient care and STDs 20071101

• Caution regarding nelfinavir use in children and pregnant women.

  AIDS clinical care 20071101

• FDA notifications. FDA provides more info in response to Viracept recall.

  AIDS alert 20071101

• Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.

  Journal of molecular graphics & modelling 20071001

• Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

  Biomedical chromatography : BMC 20071001

• Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence.

  Cell death and differentiation 20071001

• Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.

  Drug metabolism and disposition: the biological fate of chemicals 20071001

• Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

  The Journal of antimicrobial chemotherapy 20071001

• Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing.

  Antimicrobial agents and chemotherapy 20071001

• Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification.

  The Journal of antimicrobial chemotherapy 20071001

• High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.

  AIDS (London, England) 20071001

• A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients.

  Revista clinica espanola 20071001

• Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy.

  AIDS research and human retroviruses 20071001

• Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1.

  PLoS pathogens 20071001

• Viracept recommended for reinstatement in Europe.

  AIDS patient care and STDs 20071001

• Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

  The Journal of biological chemistry 20070928

• Biomedicine. HIV drug shows promise as potential cancer treatment.

  Science (New York, N.Y.) 20070907

• Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival.

  Clinical pharmacology and therapeutics 20070901

• Inhibition of P-glycoprotein activity at the primate blood-brain barrier increases the distribution of nelfinavir into the brain but not into the cerebrospinal fluid.

  Drug metabolism and disposition: the biological fate of chemicals 20070901

• In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

  Antimicrobial agents and chemotherapy 20070901

• Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070901

• Recall of AIDS drug hits world's poorest patients.

  The AIDS reader 20070901

• Pharmacologic management of overactive bladder.

  Clinical interventions in aging 20070901

• Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.

  Bioorganic & medicinal chemistry letters 20070801

• Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.

  PLoS medicine 20070801

• The renaissance of fixed dose combinations: Combivir.

  Therapeutics and clinical risk management 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• Regulation of adipocyte lipolysis by degradation of the perilipin protein: nelfinavir enhances lysosome-mediated perilipin proteolysis.

  The Journal of biological chemistry 20070727

• Computational characterization of structural role of the non-active site mutation M36I of human immunodeficiency virus type 1 protease.

  Journal of molecular biology 20070713

• Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070701

• Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008.

  AIDS (London, England) 20070701

• Viracept contaminated in Europe.

  AIDS patient care and STDs 20070701

• Antiretroviral agents and acid-base balance at delivery of the neonate.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070701

• Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070701

• Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient.

  Journal of drugs in dermatology : JDD 20070701

• Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.

  The new microbiologica 20070701

• Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070615

• Site-specific mutations in HIV-1 gp41 reveal a correlation between HIV-1-mediated bystander apoptosis and fusion/hemifusion.

  The Journal of biological chemistry 20070608

• Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070601

• Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.

  The Journal of infection 20070601

• Doxorubicin cardiomyopathy via TLR-2 stimulation: potential for prevention using current anti-retroviral inhibitors such as ritonavir and nelfinavir.

  Hematological oncology 20070601

• A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20070601

• HIV-1 protease inhibitors do not interfere with provirus transcription and host cell apoptosis induced by combined treatment TNF-alpha + TSA.

  Biochemical pharmacology 20070601

• Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.

  Pharmacotherapy 20070601

• Factors associated with poor immunologic responses despite viral suppression in markedly immunosuppressed patients.

  AIDS patient care and STDs 20070601

• Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20070601

• Antiretroviral pharmacokinetic profile: a review of sex differences.

  Gender medicine 20070601

• Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.

  Metabolic syndrome and related disorders 20070601

• Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

  Biochemical pharmacology 20070515

• HIV protease inhibitors enhance the efficacy of irradiation.

  Cancer research 20070515

• Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.

  AIDS (London, England) 20070511

• Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20070501

• Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Paronychia in an HIV-infected patient under nelfinavir therapy.

  Journal of the European Academy of Dermatology and Venereology : JEADV 20070501

• HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo.

  Apoptosis : an international journal on programmed cell death 20070501

• Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir.

  Cancer research 20070501

• HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

  PLoS computational biology 20070501

• Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.

  AIDS (London, England) 20070423

• Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.

  Journal of medicinal chemistry 20070419

• An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401

• HIV1 protease inhibitors selectively induce inflammatory chemokine expression in primary human osteoblasts.

  Antiviral research 20070401

• Expression, purification and preliminary X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease.

  Acta crystallographica. Section F, Structural biology and crystallization communications 20070401

• ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

  PLoS pathogens 20070401

• The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.

  Neoplasia (New York, N.Y.) 20070401

• Instrumental variables and interactions in the causal analysis of a complex clinical trial.

  Statistics in medicine 20070330

• High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications.

  Journal of pharmaceutical and biomedical analysis 20070312

• Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.

  The Journal of antimicrobial chemotherapy 20070301

• Comparison of echinocandin antifungals.

  Therapeutics and clinical risk management 20070301

• Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.

  Clinical pharmacology and therapeutics 20070201

• Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

  The Journal of antimicrobial chemotherapy 20070201

• HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.

  Cancer research 20070201

• HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts.

  AIDS research and human retroviruses 20070201

• Prevention of immune cell apoptosis as potential therapeutic strategy for severe infections.

  Emerging infectious diseases 20070201

• Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070101

• In silico prediction of pregnane X receptor activators by machine learning approaches.

  Molecular pharmacology 20070101

• A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

  PLoS medicine 20070101

• Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.

  AIDS research and human retroviruses 20070101

• Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).

  AIDS research and therapy 20070101

• A comparison of different protease inhibitors on coronary heart disease risk.

  Connecticut medicine 20070101

• Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

  BMC pediatrics 20070101

• HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?

  PloS one 20070101

• Super learning: an application to the prediction of HIV-1 drug resistance.

  Statistical applications in genetics and molecular biology 20070101

• Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.

  Journal of medical case reports 20070101

• A virological benefit from an induction/maintenance strategy: the Forte trial.

  Antiviral therapy 20070101

• TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines?

  Globalization and health 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children.

  BMC infectious diseases 20070101

• First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.

  Antiviral therapy 20070101

• HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms.

  AIDS research and therapy 20070101

• Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.

  AIDS research and therapy 20070101

• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  Rapid communications in mass spectrometry : RCM 20070101

• Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages.

  Antiviral therapy 20070101

• Three-year immune reconstitution in PI-sparing and PI-containing antiretroviral regimens in advanced HIV-1 disease.

  Antiviral therapy 20070101

• Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.

  Scandinavian journal of infectious diseases 20070101

• Differential drug resistance acquisition in HIV-1 of subtypes B and C.

  PloS one 20070101

• Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.

  Antiviral therapy 20070101

• Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.

  Clinical pharmacokinetics 20070101

• HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?

  Antiviral therapy 20070101

• Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005.

  AIDS research and therapy 20070101

• Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20070101

• Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition.

  Neurosurgical focus 20070101

• Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.

  Cost effectiveness and resource allocation : C/E 20070101

• Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors.

  Current medicinal chemistry 20070101

• [Intestinal microbiota of individuals who suffered occupational accidents with biological materials and underwent antiretroviral prophylaxis].

  Revista da Sociedade Brasileira de Medicina Tropical 20070101

• Analysis of HIV Protease Killing Through Caspase 8 Reveals a Novel Interaction Between Caspase 8 and Mitochondria.

  The open virology journal 20070101

• Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy.

  The open virology journal 20070101

• Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.

  Core evidence 20070101

• NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.

  British journal of cancer 20061218

• Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance.

  Bioinformatics (Oxford, England) 20061215

• Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215

• N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

  AIDS research and human retroviruses 20061201

• Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.

  AIDS (London, England) 20061128

• Evaluation of an International Pharmacopoeia method for the analysis of nelfinavir mesilate by liquid chromatography.

  Journal of chromatography. A 20061117

• Secretory aspartyl peptidase activity from mycelia of the human fungal pathogen Fonsecaea pedrosoi: effect of HIV aspartyl proteolytic inhibitors.

  Research in microbiology 20061101

• Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells.

  Diabetes, obesity & metabolism 20061101

• Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

  Pharmacogenetics and genomics 20061101

• Pharmacokinetics of nelfinavir in subjects with hepatic impairment.

  Journal of clinical pharmacology 20061101

• Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.

  International journal of STD & AIDS 20061101

• CD4 count and viral load time-courses in patients treated with highly active antiretroviral therapy and association with the CDC staging system.

  HIV medicine 20061101

• HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells.

  Neoplasia (New York, N.Y.) 20061101

• Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.

  Clinical pharmacology and therapeutics 20061001

• Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.

  Cancer research 20060915

• Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.

  The Journal of infectious diseases 20060901

• Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.

  British journal of clinical pharmacology 20060901

• Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.

  Anti-cancer drugs 20060901

• SARS: systematic review of treatment effects.

  PLoS medicine 20060901

• Membrane transporter proteins: a challenge for CNS drug development.

  Dialogues in clinical neuroscience 20060901

• Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

  Journal of medicinal chemistry 20060824

• Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.

  AIDS (London, England) 20060822

• Examining the production costs of antiretroviral drugs.

  AIDS (London, England) 20060822

• [Adherence, pharmacokinetic 'tolerance capacity' and HIV resistance development].

  Praxis 20060816

• Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases.

  The Journal of antimicrobial chemotherapy 20060801

• Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study.

  Journal of acquired immune deficiency syndromes (1999) 20060801

• Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

  Journal of acquired immune deficiency syndromes (1999) 20060801

• Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.

  British journal of clinical pharmacology 20060801

• The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir.

  British journal of clinical pharmacology 20060801

• Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring.

  Therapeutic drug monitoring 20060801

• Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.

  Lancet (London, England) 20060722

• Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.

  AIDS (London, England) 20060713

• Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.

  The Journal of antimicrobial chemotherapy 20060701

• A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.

  PLoS clinical trials 20060701

• Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.

  HIV medicine 20060701

• [Clinical and pharmacokinetic interactions between methadone and nelfinavir (Nemesia study)].

  Medicina clinica 20060610

• Determination of nelfinavir mesylate as bulk drug and in pharmaceutical dosage form by stability indicating HPLC.

  Journal of pharmaceutical and biomedical analysis 20060607

• Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.

  Antiviral research 20060601

• Cooperative contribution of gag substitutions to nelfinavir-dependent enhancement of precursor cleavage and replication of human immunodeficiency virus type-1.

  Antiviral research 20060601

• Antiretroviral drug resistance and routine therapy, Cameroon.

  Emerging infectious diseases 20060601

• Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance.

  Journal of substance abuse treatment 20060601

• Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.

  The Annals of pharmacotherapy 20060601

• Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.

  The Pediatric infectious disease journal 20060601

• Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?

  Therapeutic drug monitoring 20060601

• High HIV type 1 subtype diversity and few drug resistance mutations among seropositive people detected during the 2005 second generation HIV surveillance in Madagascar.

  AIDS research and human retroviruses 20060601

• Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.

  Microbes and infection 20060601

• Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

  Biochemistry 20060502

• Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060501

• Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.

  The Journal of general virology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.

  Clinical therapeutics 20060501

• HIV-specific cellular immune responses are stimulated by structured treatment interruption in chronically HIV-1 infected Koreans.

  Yonsei medical journal 20060430

• Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy.

  AIDS (London, England) 20060424

• Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.

  AIDS (London, England) 20060424

• Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial.

  Journal of acquired immune deficiency syndromes (1999) 20060415

• Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.

  Virology 20060410

• Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.

  The Journal of infection 20060401

• Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.

  Bioorganic & medicinal chemistry letters 20060401

• Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

  The Journal of antimicrobial chemotherapy 20060401

• Potential antivirals and antiviral strategies against SARS coronavirus infections.

  Expert review of anti-infective therapy 20060401

• Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support.

  Journal of acquired immune deficiency syndromes (1999) 20060401

• A review of nelfinavir for the treatment of HIV infection.

  Expert opinion on drug metabolism & toxicology 20060401

• Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.

  AIDS (London, England) 20060321

• Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: the role of CYP3A and P-glycoprotein.

  The Journal of pharmacology and experimental therapeutics 20060301

• Pharmacokinetic interaction of nelfinavir and methadone in intravenous drug users.

  Biopharmaceutics & drug disposition 20060301

• Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.

  PLoS medicine 20060301

• A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.

  HIV medicine 20060301

• Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.

  HIV medicine 20060301

• Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.

  Pediatrics 20060301

• In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

  Antimicrobial agents and chemotherapy 20060301

• Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients.

  The Annals of pharmacotherapy 20060301

• Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217

• Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis.

  Cell death and differentiation 20060201

• HIV gp41-induced apoptosis is mediated by caspase-3-dependent mitochondrial depolarization, which is inhibited by HIV protease inhibitor nelfinavir.

  Journal of leukocyte biology 20060201

• The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers.

  Journal of clinical pharmacology 20060201

• JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis.

  Journal of hepato-biliary-pancreatic surgery 20060201

• Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.

  AIDS alert 20060201

• Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.

  AIDS (London, England) 20060109

• Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography.

  Biomedical chromatography : BMC 20060101

• Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women.

  Diabetes/metabolism research and reviews 20060101

• HIV protease inhibitors: suppression of insulin secretion by inhibition of voltage-dependent K+ currents and anion currents.

  The Journal of pharmacology and experimental therapeutics 20060101

• Increased expression of MDR1 mRNAs and P-glycoprotein in placentas from HIV-1 infected women.

  Placenta 20060101

• Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.

  Basic & clinical pharmacology & toxicology 20060101

• Impact of long-term viral suppression in CD4+ recovery of HIV-children on Highly Active Antiretroviral Therapy.

  BMC infectious diseases 20060101

• Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India.

  BMC infectious diseases 20060101

• Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma.

  Clinical chemistry and laboratory medicine 20060101

• DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.

  BMC infectious diseases 20060101

• Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

  BMC infectious diseases 20060101

• Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients.

  Scandinavian journal of infectious diseases 20060101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20060101

• Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children.

  BMC infectious diseases 20060101

• Antiretroviral agents during pregnancy: consequences on hematologic parameters in HIV-exposed, uninfected newborn infant.

  European journal of obstetrics, gynecology, and reproductive biology 20060101

• Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy.

  Radiation oncology (London, England) 20060101

• Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG.

  Antiviral therapy 20060101

• Rapid propagation of low-fitness drug-resistant mutants of human immunodeficiency virus type 1 by a streptococcal metabolite sparsomycin.

  Antiviral chemistry & chemotherapy 20060101

• Morphologic and immunophenotypic evidence of in-situ Kaposi's sarcoma.

  BMC clinical pathology 20060101

• Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport.

  Bioconjugate chemistry 20060101

• Detection of HIV protease inhibitors in alveolar epithelial lining fluid: relevance for modulation of pneumocystis infection in the course of HAART.

  The Journal of eukaryotic microbiology 20060101

• Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice.

  Antiviral chemistry & chemotherapy 20060101

• Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal.

  PloS one 20060101

• A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.

  PloS one 20060101

• Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

  PloS one 20060101

• No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations.

  HIV clinical trials 20060101

• Cost to achieve an undetectable viral load using recommended antiretroviral regimens.

  HIV clinical trials 20060101

• Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.

  HIV clinical trials 20060101

• Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs.

  Antiviral therapy 20060101

• Nelfinavir induces adipocyte insulin resistance through the induction of oxidative stress: differential protective effect of antioxidant agents.

  Antiviral therapy 20060101

• Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.

  Antiviral therapy 20060101

• Structure-Activity Relationships of Synthetic Coumarins as HIV-1 Inhibitors.

  Bioinorganic chemistry and applications 20060101

• Molecular drug targets and structure based drug design: A holistic approach.

  Bioinformation 20060101

• [Post-exposure prophylaxis of HIV infection in out-patient clinic of hospital for infectious diseases in Warsaw in 2001-2002].

  Przeglad epidemiologiczny 20060101

• Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.

  Journal of the International AIDS Society 20060101

• Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051227

• Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

  The Journal of infectious diseases 20051201

• Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin.

  The FEBS journal 20051201

• Quadruple-2 protease inhibitors (PI)-therapy does not accelerate viral decay and suppression in PI-naive HIV-1 infected patients with severe immunosuppression and high viral load as compared with standard triple therapy.

  International journal of STD & AIDS 20051201

• Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

  The Pediatric infectious disease journal 20051201

• Increase in thyroid follicular cell tumors in nelfinavir-treated rats observed in a 2-year carcinogenicity study is consistent with a rat-specific mechanism of thyroid neoplasia.

  Human & experimental toxicology 20051201

• Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.

  AIDS (London, England) 20051104

• Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

  AIDS (London, England) 20051104

• The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk.

  AIDS (London, England) 20051104

• In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.

  Drug metabolism and disposition: the biological fate of chemicals 20051101

• Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.

  HIV medicine 20051101

• Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051015

• Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia.

  The Journal of infectious diseases 20051015

• The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.

  The Journal of infectious diseases 20051015

• A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.

  The Journal of infectious diseases 20051015

• Determination of antiretroviral agents in human serum by capillary electrophoresis.

  Journal of chromatography. A 20051014

• The application of accelerator mass spectrometry to absolute bioavailability studies in humans: simultaneous administration of an intravenous microdose of 14C-nelfinavir mesylate solution and oral nelfinavir to healthy volunteers.

  Journal of clinical pharmacology 20051001

• Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir.

  Therapeutic drug monitoring 20051001

• Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.

  British journal of clinical pharmacology 20051001

• Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein.

  Journal of virology 20051001

• Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

  The Pediatric infectious disease journal 20051001

• Nelfinavir in HIV-HCV coinfected patients: a 24-month follow-up in a cohort of 82 patients.

  AIDS research and human retroviruses 20051001

• HIV antiretroviral agents inhibit protein synthesis and decrease ribosomal protein S6 and 4EBP1 phosphorylation in C2C12 myocytes.

  AIDS research and human retroviruses 20051001

• Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.

  Current drug metabolism 20051001

• Increased thymic output in HIV-negative patients after antiretroviral therapy.

  AIDS (London, England) 20050923

• HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.

  Cancer research 20050915

• Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.

  AIDS (London, England) 20050902

• Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.

  Pharmacogenetics and genomics 20050901

• Pharmacokinetics of antivirals in neonate.

  Early human development 20050901

• Effects of 5 HIV protease inhibitors on vasomotor function and superoxide anion production in porcine coronary arteries.

  Journal of acquired immune deficiency syndromes (1999) 20050901

• The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.

  HIV medicine 20050901

• Long-term complete remission of laryngeal Kaposi's sarcoma after palliative radiotherapy.

  Nature clinical practice. Oncology 20050901

• An overview on severe acute respiratory syndrome (SARS).

  Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 20050901

• Hydrophobicity in the design of P2/P2' tetrahydropyrimidinone HIV protease inhibitors.

  Bioorganic & medicinal chemistry letters 20050815

• Transfer of antivirals across the human placenta.

  Early human development 20050801

• Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.

  Journal of medical virology 20050801

• Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.

  Bioorganic & medicinal chemistry letters 20050801

• TDM: therapeutic drug measuring or therapeutic drug monitoring?

  Therapeutic drug monitoring 20050801

• Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort.

  AIDS research and human retroviruses 20050801

• Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.

  Pharmacotherapy 20050801

• HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20050801

• Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.

  Biochemical and biophysical research communications 20050722

• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

• HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

• Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

  The Journal of clinical investigation 20050701

• Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma.

  Biological & pharmaceutical bulletin 20050701

• HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling.

  Cancer science 20050701

• Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir.

  The Journal of infectious diseases 20050615

• The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice.

  Journal of pharmaceutical sciences 20050601

• Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.

  Journal of acquired immune deficiency syndromes (1999) 20050601

• Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma.

  Therapeutic drug monitoring 20050601

• TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

  Antimicrobial agents and chemotherapy 20050601

• Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay.

  Antimicrobial agents and chemotherapy 20050601

• Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates.

  Clinics (Sao Paulo, Brazil) 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Abnormalities in plasma fatty acid composition in human immunodeficiency virus-infected children treated with protease inhibitors.

  Acta paediatrica (Oslo, Norway : 1992) 20050601

• Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525

• Nelfinavir and nevirapine side effects during pregnancy.

  AIDS (London, England) 20050520

• The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.

  HIV medicine 20050501

• Hepatotoxicity and nelfinavir: a meta-analysis.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20050501

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• The adherence to antiretroviral treatment evaluated from a hospital pharmacy: importance of the protease inhibitors pharmacological class.

  International journal of STD & AIDS 20050501

• Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.

  The Journal of antimicrobial chemotherapy 20050401

• Postexposure prophylaxis after sexual assaults: a prospective cohort study.

  Sexually transmitted diseases 20050401

• Effect of maternal use of antiretroviral agents on serum insulin levels of the newborn infant.

  Diabetes care 20050401

• Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20050401

• Lopinavir/r versus nelfinavir as salvage therapy.

  The Pediatric infectious disease journal 20050401

• Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

  PLoS medicine 20050401

• Design of HIV-1 protease inhibitors active on multidrug-resistant virus.

  Journal of medicinal chemistry 20050324

• An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children.

  AIDS (London, England) 20050304

• Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.

  The American journal of cardiology 20050301

• Assessment of the bioequivalence of two nelfinavir tablet formulations under fed and fasted conditions in healthy subjects.

  International journal of clinical pharmacology and therapeutics 20050301

• Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.

  HIV medicine 20050301

• Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

  Therapeutics and clinical risk management 20050301

• Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.

  AIDS (London, England) 20050218

• C/EBPalpha reverses the anti-adipogenic effects of the HIV protease inhibitor nelfinavir.

  Biochemical and biophysical research communications 20050211

• Mechanism-based inactivation of CYP3A by HIV protease inhibitors.

  The Journal of pharmacology and experimental therapeutics 20050201

• Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

  Pediatrics 20050201

• Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.

  European journal of clinical pharmacology 20050201

• In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.

  Biological & pharmaceutical bulletin 20050201

• Blockade of HERG channels by HIV protease inhibitors.

  Lancet (London, England) 20050201

• Immunotoxicity evaluation of nelfinavir in rats.

  Human & experimental toxicology 20050201

• Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.

  The journal of physical chemistry. B 20050113

• Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• HIV-1 genotype resistance pattern and evolution in patients failing nelfinavir-containing regimens.

  Journal of clinical laboratory analysis 20050101

• Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.

  BMC infectious diseases 20050101

• Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.

  Acta physiologica Scandinavica 20050101

• No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients.

  Annals of clinical microbiology and antimicrobials 20050101

• Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.

  Lipids in health and disease 20050101

• Molecular strategies to inhibit HIV-1 replication.

  Retrovirology 20050101

• First Dominique Dormont International Conference on 'Host-pathogen interactions in chronic infections - viral and host determinants of HCV, HCMV, and HIV infections'.

  Retrovirology 20050101

• Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

  BMC infectious diseases 20050101

• Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20050101

• The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.

  Antiviral therapy 20050101

• The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients.

  Antiviral therapy 20050101

• Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.

  Clinical pharmacokinetics 20050101

• In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs.

  Arzneimittel-Forschung 20050101

• Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

  BMC infectious diseases 20050101

• Drug-drug interactions and the pharmacotherapy of HIV infection.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101

• Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.

  BMC infectious diseases 20050101

• Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

  Antiviral therapy 20050101

• The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.

  Antiviral therapy 20050101

• Will pharmacogenomic discoveries improve HIV therapeutics?

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101

• Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.

  Journal of immune based therapies and vaccines 20050101

• Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20050101

• Nelfinavir: a review of its use in the management of HIV infection.

  Drugs 20050101

• Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study.

  Journal of translational medicine 20050101

• Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment.

  BMC infectious diseases 20050101

• Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20050101

• Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?

  Antiviral therapy 20050101

• Effectiveness of step-wise intervention plan for managing nelfinavir-associated diarrhea: a pilot study.

  HIV clinical trials 20050101

• Scutellaria baicalensis decreases ritonavir-induced nausea.

  AIDS research and therapy 20050101

• High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

  Clinical pharmacokinetics 20050101

• Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.

  International journal of immunopathology and pharmacology 20050101

• In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

  Antiviral therapy 20050101

• Safety of nelfinavir use during pregnancy. An experimental approach in rats.

  Clinical and experimental obstetrics & gynecology 20050101

• Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients.

  Clinical drug investigation 20050101

• Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.

  Journal of the International AIDS Society 20050101

• Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

  Journal of the International AIDS Society 20050101

• Genetic barriers to resistance and impact on clinical response.

  Journal of the International AIDS Society 20050101

• Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction.

  Core evidence 20050101

• A combined QM/MM approach to protein--ligand interactions: polarization effects of the HIV-1 protease on selected high affinity inhibitors.

  Journal of medicinal chemistry 20041230

• Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225

• Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.

  Journal of acquired immune deficiency syndromes (1999) 20041215

• Nelfinavir induces necrosis of 3T3F44-2A adipocytes by oxidative stress.

  Journal of acquired immune deficiency syndromes (1999) 20041215

• [Liver transplantation in a HIV-positive patient receiving potent antiretroviral therapy; the first case in The Netherlands].

  Nederlands tijdschrift voor geneeskunde 20041211

• Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19.

  Drug metabolism and disposition: the biological fate of chemicals 20041201

• Hepatic steatosis and pancreatitis associated with the use of stavudine in a patient with HIV infection.

  AJR. American journal of roentgenology 20041201

• Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20041201

• Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20041201

• Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells.

  The Journal of endocrinology 20041201

• The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.

  Clinical pharmacology and therapeutics 20041201

• Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

  PLoS medicine 20041201

• Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.

  Antiviral therapy 20041201

• Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.

  Antiviral therapy 20041201

• Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy.

  Antiviral therapy 20041201

• Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy.

  Journal of chemotherapy (Florence, Italy) 20041201

• [Serum vitamin A during pregnancy and effects on obstetrics and perinatal outcomes in HIV infected pregnant women].

  Archivos latinoamericanos de nutricion 20041201

• Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir.

  AIDS (London, England) 20041119

• Improved structure-activity relationship analysis of HIV-1 protease inhibitors using interaction kinetic data.

  Journal of medicinal chemistry 20041118

• CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

  AIDS (London, England) 20041105

• Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101

• Alternative, age- and viral load-related routes of nelfinavir resistance in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.

  The Pediatric infectious disease journal 20041101

• Atazanavir: A novel once-daily protease inhibitor.

  Drugs of today (Barcelona, Spain : 1998) 20041101

• Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015

• [Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].

  Nederlands tijdschrift voor geneeskunde 20041009

• Atazanavir.

  The Annals of pharmacotherapy 20041001

• Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors.

  Therapeutic drug monitoring 20041001

• Therapeutic drug monitoring of nelfinavir in pregnancy: a case report.

  Therapeutic drug monitoring 20041001

• Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

  Antimicrobial agents and chemotherapy 20041001

• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

  PLoS medicine 20041001

• Binding of anti-HIV drugs to human serum albumin.

  IUBMB life 20041001

• Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease.

  Biochemistry 20040928

• Subnanogram on-line column-switching liquid chromatographic-tandem mass spectrometric quantification method for nelfinavir and methoxyphenol metabolite M1 in rat plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040925

• Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.

  AIDS (London, England) 20040903

• Fosamprenavir: advancing HIV protease inhibitor treatment options.

  Expert opinion on pharmacotherapy 20040901

• Sweet's syndrome following abacavir therapy.

  Journal of the American Academy of Dermatology 20040901

• Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.

  The Journal of pediatrics 20040901

• Nelfinavir plasma concentrations are low during pregnancy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040901

• Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy.

  American journal of obstetrics and gynecology 20040901

• HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815

• Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.

  Journal of virology 20040801

• Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040801

• Resistance to HIV protease inhibitors: mechanisms and clinical consequences.

  Current drug metabolism 20040801

• Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus.

  American journal of obstetrics and gynecology 20040801

• Evaluation of endogenous pig retrovirus expression and of tumorigenicity in nude mice.

  Veterinary research communications 20040801

• Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

  Prescrire international 20040801

• SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.

  AIDS (London, England) 20040723

• Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.

  The Journal of infectious diseases 20040715

• HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

  The Journal of pharmacology and experimental therapeutics 20040701

• Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

  Journal of acquired immune deficiency syndromes (1999) 20040701

• Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV-infected patients.

  HIV medicine 20040701

• [Impairment of IRS-2 signaling in rat insulinoma INS-1 cells by nelfinavir].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20040701

• High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615

• A trial of three antiretroviral regimens in HIV-1-infected children.

  The New England journal of medicine 20040610

• HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus.

  Biochemical and biophysical research communications 20040604

• Antiviral drugs in current clinical use.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601

• Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.

  Journal of acquired immune deficiency syndromes (1999) 20040601

• Nelfinavir-induced insulin resistance is associated with impaired plasma membrane recruitment of the PI 3-kinase effectors Akt/PKB and PKC-zeta.

  Diabetologia 20040601

• Risk of birth defects associated with nelfinavir exposure during pregnancy.

  Obstetrics and gynecology 20040601

• Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.

  Molecular therapy : the journal of the American Society of Gene Therapy 20040601

• Direct interference of HIV protease inhibitors with pancreatic beta-cell function.

  Naunyn-Schmiedeberg's archives of pharmacology 20040601

• New 3-O-acyl betulinic acids from Strychnos vanprukii Craib.

  Journal of natural products 20040601

• Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.

  Pharmacotherapy 20040601

• The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.

  Antiviral therapy 20040601

• [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].

  Parassitologia 20040601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040601

• Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling.

  American journal of physiology. Cell physiology 20040501

• [HAART and pregnancy. Nelfinavir superiority in hepatotoxicity].

  MMW Fortschritte der Medizin 20040426

• Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.

  The Journal of infectious diseases 20040401

• Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction.

  Clinical pharmacology and therapeutics 20040401

• HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2.

  Molecular cancer therapeutics 20040401

• Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.

  Antiviral therapy 20040401

• Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.

  Prescrire international 20040401

• Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.

  Emerging infectious diseases 20040401

• Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.

  Current HIV/AIDS reports 20040401

• Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?

  The Journal of infectious diseases 20040315

• GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks.

  AIDS (London, England) 20040305

• Comparison of regimens as initial therapy for HIV.

  The New England journal of medicine 20040304

• Anticonvulsant and antiretroviral interactions.

  The Annals of pharmacotherapy 20040301

• In vitro studies of the effects of HAART drugs and excipients on activity of digestive enzymes.

  Pharmaceutical research 20040301

• Q fever endocarditis in HIV-infected patient.

  Emerging infectious diseases 20040301

• Protease inhibitor therapy improves protein catabolism in prepubertal children with HIV infection.

  Journal of pediatric endocrinology & metabolism : JPEM 20040301

• Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.

  Antiviral research 20040301

• Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.

  Bioorganic & medicinal chemistry letters 20040223

• Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity.

  Organic & biomolecular chemistry 20040207

• Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice.

  Endocrinology 20040201

• Newer treatments for HIV in children.

  Current opinion in pediatrics 20040201

• Mitochondrial effects of antiretroviral therapies in asymptomatic patients.

  Antiviral therapy 20040201

• Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

  Antiviral therapy 20040201

• Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.

  Antiviral therapy 20040201

• Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.

  Antiviral therapy 20040201

• Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

  AIDS (London, England) 20040123

• Structure-activity and structure-metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure.

  Bioorganic & medicinal chemistry 20040102

• Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

  The Journal of infectious diseases 20040101

• The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20040101

• Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo.

  Frontiers in bioscience : a journal and virtual library 20040101

• In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.

  Arzneimittel-Forschung 20040101

• A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102).

  HIV clinical trials 20040101

• Kinetic and thermodynamic characterization of HIV-1 protease inhibitors.

  Journal of molecular recognition : JMR 20040101

• Peptidomimetic inhibitors of HIV protease.

  Current topics in medicinal chemistry 20040101

• Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir.

  The American journal on addictions 20040101

• Health-related quality of life in HIV-infected naive patients treated with nelfinavir or nevirapine associated with ZDV/3TC (the COMBINE-QoL substudy).

  HIV clinical trials 20040101

• Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites.

  Journal of medical Internet research 20040101

• Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.

  BMC infectious diseases 20040101

• HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants.

  Cardiovascular toxicology 20040101

• Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

  Clinical pharmacokinetics 20040101

• Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.

  HIV clinical trials 20040101

• Pharmacokinetics of antiretrovirals in pregnant women.

  Clinical pharmacokinetics 20040101

• Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20040101

• The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review.

  BMC infectious diseases 20040101

• [The genetic variability of the protease-encoding region in HIV-1 A isolates and in CRF03_AB recombinants as observed in the CIS territory].

  Voprosy virusologii 20040101

• [Development of microchips for the detection of mutations of HIV-1 variability to protease inhibitors and the usage results].

  Voprosy virusologii 20040101

• Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV)- or lopinavir/ritonavir (LPV/r)-related diarrhea.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20040101

• Anti-HIV agents. Nelfinavir levels during pregnancy.

  TreatmentUpdate 20040101

• Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.

  Biochemistry 20031230

• Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20031215

• Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

  The New England journal of medicine 20031211

• Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

  The New England journal of medicine 20031211

• [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].

  MMW Fortschritte der Medizin 20031211

• Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.

  AIDS (London, England) 20031205

• Absence of embryo-fetal toxicity in rats or rabbits following oral dosing with nelfinavir.

  Regulatory toxicology and pharmacology : RTP 20031201

• Absence of reproductive and developmental toxicity in rats following oral dosing with nelfinavir.

  Regulatory toxicology and pharmacology : RTP 20031201

• Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir.

  Pharmacology 20031201

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031201

• [Immunological, virological and clinical response in patients infected with HIV after highly active antiviral therapy with nelfinavir: prospective cohort study].

  Enfermedades infecciosas y microbiologia clinica 20031201

• A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir.

  Antiviral therapy 20031201

• A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20031201

• Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.

  Dermatology online journal 20031201

• HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.

  The Journal of biological chemistry 20031128

• Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.

  Biochemistry 20031125

• Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation.

  AIDS (London, England) 20031121

• Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.

  British journal of cancer 20031117

• Small hydroxyethylene-based peptidomimetics inhibiting both HIV-1 and C. albicans aspartic proteases.

  Bioorganic & medicinal chemistry 20031103

• A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.

  The Journal of clinical endocrinology and metabolism 20031101

• Nelfinavir safe and effective in HIV/HCV patients.

  AIDS patient care and STDs 20031101

• Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation.

  AIDS (London, England) 20031017

• Modulation of the LDL receptor and LRP levels by HIV protease inhibitors.

  Journal of lipid research 20031001

• Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031001

• Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

  Antimicrobial agents and chemotherapy 20031001

• Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults.

  Therapeutic drug monitoring 20031001

• Successful treatment of hepatitis C in a patient with advanced AIDS and decompensated cirrhosis.

  The AIDS reader 20031001

• Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088).

  Antiviral therapy 20031001

• Atazanavir (Reyataz).

  Project Inform perspective 20031001

• Atazanavir: improving the HIV protease inhibitor class.

  Expert review of anti-infective therapy 20031001

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• Effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.

  The Journal of antimicrobial chemotherapy 20030901

• Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.

  The Journal of antimicrobial chemotherapy 20030901

• Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.

  The Annals of pharmacotherapy 20030901

• A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

  The Journal of infectious diseases 20030901

• In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.

  Antimicrobial agents and chemotherapy 20030901

• Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20030901

• Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.

  Pediatrics 20030901

• Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth.

  The Lancet. Oncology 20030901

• [Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit].

  Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20030901

• The binding of HIV-1 protease inhibitors to human serum proteins.

  Biophysical chemistry 20030901

• Pfizer announces free drug program.

  AIDS patient care and STDs 20030901

• Characterizing classes of antiretroviral drugs by genotype.

  Statistics in medicine 20030830

• Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial.

  Annals of internal medicine 20030819

• Summaries for patients. Does marijuana affect viral loads in people with HIV?

  Annals of internal medicine 20030819

• The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Viral dynamics and their relations to baseline factors and longer term virologic responses in treatment-naive HIV-1-infected patients receiving abacavir in combination with HIV-1 protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20030815

• Primary nelfinavir (NFV)-associated resistance mutations during a follow-up period of 108 weeks in protease inhibitor naïve patients treated with NFV-containing regimens in an HIV clinic cohort.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20030801

• Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.

  Annals of internal medicine 20030715

• 'All-in-One Assay', a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations.

  Journal of virological methods 20030701

• HIV protease inhibitors acutely impair glucose-stimulated insulin release.

  Diabetes 20030701

• Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.

  Journal of acquired immune deficiency syndromes (1999) 20030701

• FDA notifications. New dosing option approved for Viracept.

  AIDS alert 20030701

• pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.

  AIDS research and human retroviruses 20030701

• Less dose burden for Viracept.

  AIDS patient care and STDs 20030701

• Rapid enzymatic test for phenotypic HIV protease drug resistance.

  Biological chemistry 20030701

• Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

  AIDS (London, England) 20030701

• Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.

  The Journal of infectious diseases 20030615

• Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma.

  Therapeutic drug monitoring 20030601

• Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.

  Therapeutic drug monitoring 20030601

• Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030601

• Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

  Antiviral therapy 20030601

• Comparison of nine resistance interpretation systems for HIV-1 genotyping.

  Antiviral therapy 20030601

• Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525

• Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

  AIDS (London, England) 20030523

• Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women.

  AIDS (London, England) 20030523

• Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.

  Clinical pharmacology and therapeutics 20030501

• Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants.

  Antiviral research 20030501

• Factors associated with accelerated atherosclerosis in HIV-1-infected persons treated with protease inhibitors.

  AIDS patient care and STDs 20030501

• [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for 'once daily' administration].

  MMW Fortschritte der Medizin 20030428

• [No selection of mutations. 908 raises genetic resistance barrier].

  MMW Fortschritte der Medizin 20030428

• [A light meal at the same time is enough. Advantages of natural enhancement of nelfinavir].

  MMW Fortschritte der Medizin 20030428

• Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425

• Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.

  Journal of medicinal chemistry 20030424

• Brief report: efficacy and treatment-limiting toxicity with the concurrent use of lopinavir/ritonavir and a third protease inhibitor in treatment-experienced HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20030415

• Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.

  AIDS (London, England) 20030411

• Sildenafil does not alter nelfinavir pharmacokinetics.

  Therapeutic drug monitoring 20030401

• Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.

  The Annals of pharmacotherapy 20030401

• Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

  The Journal of infectious diseases 20030401

• NEAT results released.

  AIDS patient care and STDs 20030401

• Resistance data also presented.

  AIDS patient care and STDs 20030401

• Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.

  Antiviral therapy 20030401

• Prevalence and virologic consequences of HIV-1 genotype mutations detected in a cohort of 161 Italian patients receiving a nelfinavir-based highly active antiretroviral therapy.

  Journal of chemotherapy (Florence, Italy) 20030401

• [Complete immune and clinical recovery after highly active antiretroviral therapy in advanced vertically HIV-1 infected children].

  Medicina clinica 20030329

• HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.

  AIDS (London, England) 20030307

• Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.

  AIDS (London, England) 20030307

• Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

  Pediatrics 20030301

• Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.

  AIDS research and human retroviruses 20030301

• Prospective comparison of first-line nelfinavir therapy versus nelfinavir introduction in rescue antiretroviral regimens.

  AIDS patient care and STDs 20030301

• [Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].

  Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 20030301

• Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy.

  European journal of medical research 20030221

• Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.

  The Journal of infectious diseases 20030215

• Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations.

  AIDS (London, England) 20030214

• Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205

• Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations.

  Therapeutic drug monitoring 20030201

• Effect of indinavir on the intestinal exsorption of amprenavir, saquinavir and nelfinavir after intravenous administration in rats.

  Biological & pharmaceutical bulletin 20030201

• Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

  Journal of mass spectrometry : JMS 20030201

• Pharmacokinetics, food intake requirements and tolerability of once-daily combinations of nelfinavir and low-dose ritonavir in healthy volunteers.

  British journal of clinical pharmacology 20030201

• Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea.

  The American journal of gastroenterology 20030201

• Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.

  Virology 20030201

• Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma.

  Journal of chromatographic science 20030201

• SOLO trial results released.

  AIDS patient care and STDs 20030201

• Protease inhibitor drug levels in the management of human immunodeficiency virus-1 antiretroviral therapy.

  International journal of STD & AIDS 20030201

• Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.

  Antiviral therapy 20030201

• A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.

  Biochemistry 20030128

• Inhibition of TNF-alpha mediated cell death by HIV-1 specific protease inhibitors.

  European journal of medical research 20030128

• A process in need is a process indeed: scalable enantioselective synthesis of chiral compounds for the pharmaceutical industry.

  Chemistry (Weinheim an der Bergstrasse, Germany) 20030120

• Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030115

• Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors.

  AIDS (London, England) 20030103

• Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.

  The Journal of pharmacology and experimental therapeutics 20030101

• Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

  Journal of acquired immune deficiency syndromes (1999) 20030101

• Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.

  HIV medicine 20030101

• The use of calcium carbonate in nelfinavir-associated diarrhoea in HIV-1-infected patients.

  HIV medicine 20030101

• Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

  The Pediatric infectious disease journal 20030101

• Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.

  The Pediatric infectious disease journal 20030101

• Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors.

  The Pediatric infectious disease journal 20030101

• Effects of nelfinavir and its M8 metabolite on lymphocyte P-glycoprotein activity during antiretroviral therapy.

  Clinical pharmacology and therapeutics 20030101

• In vitro activity of potential anti-poxvirus agents.

  Antiviral research 20030101

• Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

  Drugs 20030101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20030101

• Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.

  BMC infectious diseases 20030101

• Pharmacokinetic interactions with rifampicin : clinical relevance.

  Clinical pharmacokinetics 20030101

• Atazanavir.

  Drugs 20030101

• Inhibition of cytochrome P450 3A: relevant drug interactions in gastroenterology.

  Digestion 20030101

• Bone appetite--using food to boost your Viracept.

  Positively aware : the monthly journal of the Test Positive Aware Network 20030101

• Clinical pharmacokinetics of atorvastatin.

  Clinical pharmacokinetics 20030101

• L-glutamine supplementation improves nelfinavir-associated diarrhea in HIV-infected individuals.

  HIV clinical trials 20030101

• Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.

  The Cochrane database of systematic reviews 20030101

• Recurrent pneumococcal meningitis in a splenectomised HIV-infected patient.

  Annals of clinical microbiology and antimicrobials 20030101

• Differences in durability of treatment with initial PI-based regimens.

  HIV clinical trials 20030101

• Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects.

  Drug metabolism and pharmacokinetics 20030101

• [AIDS and hemophilia in pediatrics: report of a case].

  Revista cubana de medicina tropical 20030101

• Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. New formulation of nelfinavir on the way.

  TreatmentUpdate 20030101

• Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Does Roche's nelfinavir cause less diarrhea?

  TreatmentUpdate 20030101

• Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients.

  The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses 20030101

• Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.

  Journal of molecular biology 20021206

• Diurnal variation of plasma protease inhibitor concentrations.

  AIDS (London, England) 20021206

• Relationships between structure and interaction kinetics for HIV-1 protease inhibitors.

  Journal of medicinal chemistry 20021205

• Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.

  Journal of medical virology 20021201

• Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.

  Drug metabolism and disposition: the biological fate of chemicals 20021201

• Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.

  Journal of acquired immune deficiency syndromes (1999) 20021201

• Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

  Antiviral therapy 20021201

• Chronic cough induced by abacavir apart from a context of hypersensitivity.

  Allergie et immunologie 20021201

• Estimating the length of the first antiretroviral therapy regiment durability in São Paulo, Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20021201

• NEAT trial releases results.

  AIDS patient care and STDs 20021201

• Nelfinavir tolerated in HCV patients.

  AIDS patient care and STDs 20021201

• Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021115

• Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

  The Journal of infectious diseases 20021115

• Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021115

• New anti-HIV agents and targets.

  Medicinal research reviews 20021101

• Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

  Diabetes 20021101

• Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers.

  Pharmaceutical research 20021101

• Supplement fix for nelfinavir-related diarrhea.

  TreatmentUpdate 20021101

• Limited effect of food composition on the pharmacokinetics of nelfinavir administered twice daily.

  European journal of medical research 20021029

• Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS.

  Journal of pharmaceutical and biomedical analysis 20021015

• Interactions between recreational drugs and antiretroviral agents.

  The Annals of pharmacotherapy 20021001

• Long-term culture of HIV-1-infected cells with the transcription inhibitor K-37.

  Antiviral research 20021001

• Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance.

  Therapeutic drug monitoring 20021001

• Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.

  Journal of virological methods 20021001

• Symptomatic orthostasis with extended-release nifedipine and protease inhibitors.

  Pharmacotherapy 20021001

• [Antiretroviral therapy with nelfinavir for patient infected, by HIV and secondary diabetes mellitus due to indinavir].

  Medicina clinica 20020928

• Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.

  AIDS research and human retroviruses 20020920

• Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

  The Journal of infectious diseases 20020901

• Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.

  The Journal of infectious diseases 20020901

• Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20020901

• The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients.

  Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 20020901

• Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.

  Clinical and diagnostic laboratory immunology 20020901

• Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations.

  Medical science monitor : international medical journal of experimental and clinical research 20020901

• Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity.

  Antiviral therapy 20020901

• Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.

  Antiviral therapy 20020901

• [HIV genotypic mutation selectively induced by the protease inhibitor nelfinavir at codon 30. Case series and consequences for antiretroviral management].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20020901

• Predictors of treatment failure during highly active antiretroviral therapy (racing trial).

  European journal of medical research 20020830

• Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients.

  AIDS (London, England) 20020816

• The pharmacokinetics of nelfinavir in HIV-1-infected children.

  Therapeutic drug monitoring 20020801

• Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20020801

• Low-dose ritonavir moderately enhances nelfinavir exposure.

  Clinical pharmacology and therapeutics 20020801

• Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir.

  Clinical pharmacology and therapeutics 20020801

• Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20020801

• Toxoplasmic encephalitis in an HIV infected pregnant woman: successful outcome for both mother and child.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20020801

• Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

  AIDS (London, England) 20020726

• Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.

  European journal of medical research 20020724

• New class of HIV integrase inhibitors that block viral replication in cell culture.

  Current biology : CB 20020723

• New developments in anti-HIV chemotherapy.

  Biochimica et biophysica acta 20020718

• Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715

• Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

  JAMA 20020710

• Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.

  Biochemistry 20020709

• Structure-based design and synthesis of HIV-1 protease inhibitors employing beta-D-mannopyranoside scaffolds.

  Bioorganic & medicinal chemistry letters 20020708

• Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).

  AIDS (London, England) 20020705

• Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.

  Proteins 20020701

• In vitro antiviral interaction of lopinavir with other protease inhibitors.

  Antimicrobial agents and chemotherapy 20020701

• Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.

  Journal of medical virology 20020701

• Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance.

  Journal of acquired immune deficiency syndromes (1999) 20020701

• Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases.

  Journal of acquired immune deficiency syndromes (1999) 20020701

• Efavirenz liquid formulation in human immunodeficiency virus-infected children.

  The Pediatric infectious disease journal 20020701

• Pharmacokinetics of saquinavir in children during long term treatment.

  The Pediatric infectious disease journal 20020701

• Increasing choices for HIV therapy.

  The New England journal of medicine 20020627

• Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

  The New England journal of medicine 20020627

• Study of different off-line sample processing procedures and the measurement of antibiotic and antiviral levels in human serum by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020625

• Reduced intravertebral bone marrow fat in HIV-infected men.

  AIDS (London, England) 20020614

• Adhesive capsulitis of the shoulder in an HIV patient treated with nelfinavir.

  AIDS (London, England) 20020614

• Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry.

  Biomedical chromatography : BMC 20020601

• Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors.

  Antimicrobial agents and chemotherapy 20020601

• High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.

  Therapeutic drug monitoring 20020601

• HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options.

  Journal of acquired immune deficiency syndromes (1999) 20020601

• A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.

  Antiviral therapy 20020601

• A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).

  Antiviral therapy 20020601

• The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.

  The Southeast Asian journal of tropical medicine and public health 20020601

• Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

  The Journal of biological chemistry 20020531

• Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.

  AIDS research and human retroviruses 20020520

• Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.

  The Journal of infectious diseases 20020515

• Needlestick transmission of hepatitis C.

  JAMA 20020508

• Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity.

  AIDS (London, England) 20020503

• Prescribing practices in a population-based HIV postexposure prophylaxis program.

  AIDS (London, England) 20020503

• Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• Paracardial lipodystrophy versus pericardial effusion in HIV positive patients.

  Heart (British Cardiac Society) 20020501

• Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report.

  American journal of hypertension 20020501

• Male sexual dysfunction associated with antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20020501

• Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Transplacental passage of protease inhibitors at delivery.

  AIDS (London, England) 20020412

• Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401

• Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020401

• Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.

  Therapeutic drug monitoring 20020401

• Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection.

  Pediatrics 20020401

• Long-term response in patients receiving HAART including nelfinavir: experience from two Italian centers.

  Journal of chemotherapy (Florence, Italy) 20020401

• The utility of inhibitory quotients in determining the relative potency of protease inhibitors.

  AIDS (London, England) 20020329

• Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.

  AIDS (London, England) 20020329

• The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir.

  AIDS (London, England) 20020308

• Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

  AIDS (London, England) 20020308

• Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study.

  AIDS (London, England) 20020308

• Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.

  Lancet (London, England) 20020302

• [Acute coronary syndromes in patients treated with HIV protease inhibitors].

  Presse medicale (Paris, France : 1983) 20020302

• Nelfinavir urinary stones.

  The Journal of urology 20020301

• Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectrometry: important factors for method optimization.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20020301

• Metabolic response to a C-glucose load in human immunodeficiency virus patients before and after antiprotease therapy.

  Metabolism: clinical and experimental 20020301

• Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection.

  Clinical pharmacology and therapeutics 20020301

• Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.

  Journal of pharmaceutical sciences 20020301

• Delayed recovery of effector memory CD4+ T cells by highly active antiretroviral therapy in a patient with HIV-1 infection.

  The Tohoku journal of experimental medicine 20020301

• Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor.

  The Pediatric infectious disease journal 20020301

• CD36 deficiency induced by antiretroviral therapy.

  AIDS (London, England) 20020215

• Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort.

  AIDS (London, England) 20020215

• A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

  Journal of virology 20020201

• Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

  Pediatrics 20020201

• In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.

  The Journal of pharmacy and pharmacology 20020201

• Efficacy of highly active antiretroviral therapy in HIV-1 infected children.

  The Lancet. Infectious diseases 20020201

• Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.

  European journal of medical research 20020129

• Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

  AIDS (London, England) 20020125

• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

  Lancet (London, England) 20020105

• Effects of antiretroviral drug combinations on the differentiation of adipocytes.

  AIDS (London, England) 20020104

• Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.

  AIDS (London, England) 20020104

• Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

  AIDS (London, England) 20020104

• Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.

  HIV clinical trials 20020101

• CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro.

  Xenobiotica; the fate of foreign compounds in biological systems 20020101

• Atazanavir demonstrates antiviral efficacy and a favorable lipid profile at 48 weeks.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20020101

• Cutaneous drug reaction case reports: from the world literature.

  American journal of clinical dermatology 20020101

• Retroviral proteases.

  Genome biology 20020101

• Zidovudine: a review of its use in the management of vertically-acquired pediatric HIV infection.

  Paediatric drugs 20020101

• Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.

  Antiviral chemistry & chemotherapy 20020101

• Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.

  Antiviral chemistry & chemotherapy 20020101

• [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ].

  Therapie 20020101

• Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.

  HIV clinical trials 20020101

• [Prophylactic antiretroviral therapy after sexual exposure to HIV: 93 cases].

  Annales de dermatologie et de venereologie 20020101

• A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.

  West African journal of medicine 20020101

• Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.

  Clinical pharmacokinetics 20020101

• Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.

  HIV clinical trials 20020101

• Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.

  HIV clinical trials 20020101

• Management of protease inhibitor-associated hyperlipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011215

• Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20011201

• Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection.

  Therapeutic drug monitoring 20011201

• Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy.

  Swiss medical weekly 20011201

• Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.

  Antiviral therapy 20011201

• Genotypic correlates of resistance to HIV-1 protease inhibitors on longitudinal data: the role of secondary mutations.

  Antiviral therapy 20011201

• [Tuberculosis among HIV-infected persons in Norway].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20011130

• Drugs for HIV infection.

  The Medical letter on drugs and therapeutics 20011126

• The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.

  Journal of medicinal chemistry 20011122

• Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir.

  Carbohydrate research 20011121

• Effect of adherence to newly initiated antiretroviral therapy on plasma viral load.

  AIDS (London, England) 20011109

• Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels.

  AIDS (London, England) 20011109

• New developments in anti-HIV chemotherapy.

  Current medicinal chemistry 20011101

• DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.

  Antimicrobial agents and chemotherapy 20011101

• Cheap AIDS drugs for developing countries.

  Trends in cell biology 20011101

• Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy.

  Metabolism: clinical and experimental 20011101

• Hepatotoxicity with antiretroviral treatment of pregnant women.

  Obstetrics and gynecology 20011101

• Lopinavir-Ritonavir: a new protease inhibitor.

  Pharmacotherapy 20011101

• Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.

  Lancet (London, England) 20011020

• Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

  AIDS (London, England) 20011019

• HIV-protease inhibitors alter retinoic acid synthesis.

  AIDS (London, England) 20011019

• Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011015

• Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.

  Journal of medicinal chemistry 20011011

• Growth in human immunodeficiency virus type 1-infected children treated with protease inhibitors.

  European journal of pediatrics 20011001

• Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile.

  Journal of chemotherapy (Florence, Italy) 20011001

• Roche gives in to Brazil over AIDS drug.

  The Lancet. Infectious diseases 20011001

• An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy.

  Neurology 20010925

• Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.

  AIDS research and human retroviruses 20010920

• Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

  The Journal of biological chemistry 20010914

• Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.

  Journal of medicinal chemistry 20010913

• Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

  Archives of internal medicine 20010910

• Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR.

  The Journal of biological chemistry 20010907

• Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.

  Antiviral research 20010901

• Long-term response for nelfinavir.

  AIDS patient care and STDs 20010901

• Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.

  Antiviral therapy 20010901

• Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss.

  Blood 20010815

• Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

  The New England journal of medicine 20010809

• Antiretroviral therapy for previously treated patients.

  The New England journal of medicine 20010809

• Antiviral drugs: current state of the art.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801

• HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.

  Journal of acquired immune deficiency syndromes (1999) 20010801

• Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay.

  Therapeutic drug monitoring 20010801

• Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

  Therapeutic drug monitoring 20010801

• Lipid abnormalities in a healthcare worker receiving HIV prophylaxis.

  International journal of STD & AIDS 20010801

• Antiretroviral rounds. When success is a pain.

  AIDS clinical care 20010801

• Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome.

  International journal of dermatology 20010801

• Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

  The Pediatric infectious disease journal 20010801

• P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

  AIDS (London, England) 20010727

• High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction.

  Journal of chromatography. B, Biomedical sciences and applications 20010715

• Capillary electrophoretic separation of protease inhibitors used in human immunodeficiency virus therapy.

  Journal of chromatography. A 20010713

• Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir.

  AIDS (London, England) 20010706

• CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.

  The British journal of ophthalmology 20010701

• Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20010701

• Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

  The Journal of infectious diseases 20010615

• The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design.

  Archives of biochemistry and biophysics 20010615

• Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010615

• Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010601

• Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.

  International journal of STD & AIDS 20010601

• Design and synthesis of a conformationally restricted trans peptide isostere based on the bioactive conformations of saquinavir and nelfinavir.

  The Journal of organic chemistry 20010601

• The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.

  Diabetes 20010601

• Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.

  International journal of antimicrobial agents 20010601

• The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.

  Journal of acquired immune deficiency syndromes (1999) 20010601

• The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.

  Journal of the American Dietetic Association 20010601

• Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.

  Antiviral therapy 20010601

• AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.

  Antiviral therapy 20010601

• Nelfinavir in expanded postexposure prophylaxis causing acute hepatitis with cholestatic features: two case reports.

  Infection control and hospital epidemiology 20010601

• Protease inhibitors and blood sugar problems.

  TreatmentUpdate 20010601

• Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

  AIDS (London, England) 20010525

• Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment.

  AIDS (London, England) 20010525

• Editorial comment on Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.

  AIDS (London, England) 20010525

• Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.

  AIDS (London, England) 20010525

• Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010515

• Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Biomedical sciences and applications 20010505

• P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20010501

• Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

  Drug metabolism and disposition: the biological fate of chemicals 20010501

• Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors.

  European journal of biochemistry 20010501

• Nelfinavir desensitization.

  The Annals of pharmacotherapy 20010501

• Ergotism related to interaction between nelfinavir and ergotamine.

  The American journal of medicine 20010501

• Structure-activity studies of FIV and HIV protease inhibitors containing allophenylnorstatine.

  Bioorganic & medicinal chemistry 20010501

• A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• Lack of association between pregnancy and selected gastrointestinal adverse events among women prescribed nelfinavir.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology.

  Analytical biochemistry 20010415

• Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.

  Journal of chromatography. A 20010413

• Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport.

  AIDS (London, England) 20010413

• Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities.

  Antimicrobial agents and chemotherapy 20010401

• Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010401

• Gynecomastia associated with highly active antiretroviral therapy.

  The Annals of pharmacotherapy 20010401

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.

  Journal of acquired immune deficiency syndromes (1999) 20010401

• Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

  AIDS patient care and STDs 20010401

• Principles and practice of HIV-protease inhibitor pharmacoenhancement.

  HIV medicine 20010401

• Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.

  AIDS (London, England) 20010330

• Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors.

  European journal of medical research 20010326

• Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.

  The Journal of infectious diseases 20010301

• Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010301

• The safety and antiviral effect of protease inhibitors in children.

  Pharmacotherapy 20010301

• Phase III trials for new PI.

  AIDS patient care and STDs 20010301

• Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir.

  Antiviral therapy 20010301

• An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy.

  AIDS (London, England) 20010216

• Failure of postexposure prophylaxis after sexual exposure to HIV.

  AIDS (London, England) 20010216

• Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.

  AIDS research and human retroviruses 20010210

• Genetic analysis of hiv type 1 strains in bujumbura (burundi): predominance of subtype c variant.

  AIDS research and human retroviruses 20010210

• Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.

  Drug metabolism and disposition: the biological fate of chemicals 20010201

• Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography.

  Therapeutic drug monitoring 20010201

• Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study.

  International journal of STD & AIDS 20010201

• Pharmacology and clinical experience with saquinavir.

  Expert opinion on pharmacotherapy 20010201

• [Resistance to protease inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20010201

• Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.

  AIDS (London, England) 20010126

• The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.

  AIDS (London, England) 20010126

• Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.

  AIDS research and human retroviruses 20010120

• The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.

  AIDS (London, England) 20010105

• Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

  Journal of clinical laboratory analysis 20010101

• Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20010101

• The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.

  Drugs 20010101

• Saquinavir soft gelatin capsule: a comparative safety review.

  Drug safety 20010101

• New developments in anti-HIV chemotherapy.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.

  Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal 20010101

• Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.

  Journal of biological regulators and homeostatic agents 20010101

• Development of HIV protease inhibitors: a survey.

  Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques 20010101

• A peptide inhibitor of HIV-1 protease using alpha, beta- dehydro residues: a structure based computer model.

  Indian journal of biochemistry & biophysics 20010101

• Kaletra versus nelfinavir.

  TreatmentUpdate 20010101

• Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.

  HIV clinical trials 20010101

• A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.

  HIV clinical trials 20010101

• Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure.

  HIV clinical trials 20010101

• Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes.

  Antiviral chemistry & chemotherapy 20010101

• Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.

  Clinical laboratory 20010101

• Randomized salvage therapy with saquinavir-ritonavir versus saquinavir-nelfinavir for highly protease inhibitor-experienced HIV-infected patients.

  HIV clinical trials 20010101

• The use of efavirenz as a part of late rescue antiretroviral treatment.

  HIV clinical trials 20010101

• Disseminated manifestation of Kaposi's Sarcoma in newly diagnosed AIDS in an african female.

  Medical science monitor : international medical journal of experimental and clinical research 20010101

• Viracept combination therapy as initial HAART demonstrates long-term response.

  The Journal of the Association of Nurses in AIDS Care : JANAC 20010101

• Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.

  HIV clinical trials 20010101

• Caution with nelfinavir and some lipid-lowering drugs.

  TreatmentUpdate 20010101

• 'In vitro' antifungal activity of protease inhibitors.

  Mycopathologia 20010101

• [Drug combination therapy for children infected with HIV/AIDS--own experience].

  Przeglad epidemiologiczny 20010101

• Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

  Biological & pharmaceutical bulletin 20001201

• Inhibition of HIV-1 protease by a boron-modified polypeptide.

  Biochemical pharmacology 20001001

• Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.

  AIDS (London, England) 20000908

• Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors.

  Journal of medicinal chemistry 20000907

• In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632.

  Antimicrobial agents and chemotherapy 20000901

• Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.

  Antimicrobial agents and chemotherapy 20000901

• In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs.

  Antiviral therapy 20000901

• BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

  Antimicrobial agents and chemotherapy 20000801

• Structural and kinetic analyses of the protease from an amprenavir-resistant human immunodeficiency virus type 1 mutant rendered resistant to saquinavir and resensitized to amprenavir.

  Journal of virology 20000801

• Didanosine-induced hepatitis.

  The American journal of gastroenterology 20000801

• Small molecule inhibitor of HIV-1 nuclear import suppresses HIV-1 replication in human lymphoid tissue ex vivo: a potential addition to current anti-HIV drug repertoire.

  Antiviral research 20000801

• Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.

  Bioorganic & medicinal chemistry letters 20000605

• A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir.

  Journal of virology 20000501

• In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.

  The Journal of infectious diseases 20000501

• Protease inhibitors: current status and future prospects.

  Journal of medicinal chemistry 20000210

• A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.

  AIDS (London, England) 20000128

• Unexplained thrombosis in HIV-infected patients receiving protease inhibitors: report of seven cases.

  The American journal of medicine 19991201

• Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species.

  Antimicrobial agents and chemotherapy 19991001

• Viracept and irregular heartbeat warning.

  The Body positive 19991001

• Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.

  Journal of medicinal chemistry 19990923

• Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.

  The Journal of biological chemistry 19990820

• Symptomatic junctional bradycardia after treatment with nelfinavir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19990801

• A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin.

  Internal medicine (Tokyo, Japan) 19990301

• Prediction of aryl hydrocarbon receptor-mediated enzyme induction of drugs and chemicals by mRNA quantification.

  Chemical research in toxicology 19981201

• Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus.

  Virology 19981025

• Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

  Antimicrobial agents and chemotherapy 19981001

• Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors.

  Chemistry & biology 19981001

• Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.

  The New England journal of medicine 19980730

• S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 19980601

• Nelfinavir associated with peripheral neuropathy in an HIV-infected patient.

  Infection 19980101

• Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.

  Journal of medicinal chemistry 19971121

• Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.

  Antiviral research 19971101

• Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.

  Antimicrobial agents and chemotherapy 19971001

• Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor.

  Antimicrobial agents and chemotherapy 19970501

• Escape mutants of HIV-1 proteinase: enzymic efficiency and susceptibility to inhibition.

  Biochimica et biophysica acta 19970425

• Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.

  Antimicrobial agents and chemotherapy 19960201

• International Congress on Chemotherapy.

  GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 19950901

• Educating the learning disabled adolescent about sexuality.

  Journal of learning disabilities 19791101